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Inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC)
are two highly aggressive breast cancer subtypes associated with a poor outcome.
Despite sensitivity to current treatment, these breast cancers subtypes have a high
recurrence rate and proclivity to metastasize early. The aggressiveness of IBC and
TNBC have been linked to CSCs and epithelial to mesenchymal transition (EMT),
which are critical features of breast cancer progression and metastasis. The clinical
challenge faced in the treatment of IBC and TNBC is finding a treatment strategy to
target the cancer stem-like (CSC) population to block metastasis. Cyclooxygenase-2
(COX-2) and receptor activator of nuclear factor kappa B ligand/receptor activator of
nuclear factor kappa B (RANKL/RANK) pathway mediate an inflammatory response
linked to breast cancer progression. However, the mechanism of how COX-2 and
RANKL/RANK regulates the progression of IBC and TNBC, respectively, is unclear.
Therefore, we investigated COX-2 and RANKL/RANK in IBC and TNBC. We
hypothesize that targeted inhibition of COX-2 and RANK in IBC and TNBC,
respectively, could eradicate CSCs to suppress tumor progression.
We observed elevated COX-2 levels in EGFR-positive IBC cells and a
significant correlation between COX-2 and EGFR gene expression in IBC tumors. How
iii

COX-2 linked to CSCs and regulates IBC progression is not well understood. We
hypothesize COX-2 to be critical for IBC progression through regulation of the CSC
population. Celecoxib, a selective COX-2 inhibitor, has anti-tumorigenic effects by
reducing breast cancer cell migration and invasion. Celecoxib treatment in an IBC
xenograft mouse model reversed EMT and downregulated expression of the embryonic
stem cell regulator Nodal. We concluded COX-2 regulation of the CSCs through Nodal
contributed to the progression of IBC and targeting the COX-2 has clinical relevance in
blocking the progression of IBC.
RANKL/RANK pathway promotes the invasion, EMT and mammary epithelial
stem cell population. We observed elevated expression in TNBC tumors and RANKL to
be an independent prognostic factor for worse outcome in RANK-positive TNBC
patients. How RANK promotes TNBC progression is not clear. We hypothesize that
suppression of RANK inhibits TNBC progression through eradication of CSCs. We
observed the suppression of RANK to reduce MDA-MB-231 cell migration and
invasion, and mammosphere formation. Stem cell genes, implicated in inflammatory
signaling, were down-regulated in MDA-MB-231 RANK shRNA cells.
Collectively, our findings suggest COX-2 and RANK to regulate of CSCs in IBC
and TNBC potentially through mediating an inflammatory response. Future pre-clinical
studies are needed to further interrogate COX-2 and RANK as novel therapeutic
targets for IBC and TNBC.
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CHAPTER 1: INTRODUCTION
1.1 BREAST CANCER
For 2014, it is predicted that about 235,000 new cases of breast cancer will be
diagnosed, and about 40,000 breast cancer patients are expected to die from the
disease (1). While we are making advancements in breast cancer treatments, we are
still met with the challenge of finding treatments to inhibit metastasis, a leading cause
of death in breast cancer patients. Breast cancer metastasis is a complex process
preceded by the development of resistance to treatment or recurrence which is often
associated with aggressive breast cancer subtypes. The multistage progression of
breast cancer is as follows: 1) normal mammary cells, 2) atypical ductal hyperplasia, 3)
ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), 4) invasive breast
cancer, and 5) metastatic breast cancer (2, 3). While stage I and II breast cancer
patients have a better prognosis, the locally advanced and metastatic breast cancers
stage III and IV, have a poorer prognosis (4). The current treatment strategy for
advanced stage breast cancers includes doxorubicin or taxane-based neoadjuvant
chemotherapy followed by surgery and adjuvant chemotherapy paclitaxel and/or
anthracycline. Patients may also receive radiotherapy and/or hormone receptor
targeted therapy (5). Depending upon the molecular breast cancer subtype, luminal,
basal-like, or normal, hormone receptor targeted therapy may be administered as part
of the treatment regimen. Breast tumors associated with a particular intrinsic molecular
subtype, luminal (non-HER2-positive), HER2-positive, basal-like, or triple-negative,
express molecular markers, EGFR, ER and/or HER2, which can be targeted for
treatment (6, 7). As a basal marker and molecular therapeutic target of interest for
1

aggressive breast cancers, the epidermal growth factor receptor (EGFR) is under
intense investigation.

1.2

EPIDERMAL GROWTH FACTOR RECEPTOR
Since the first discovery of gene amplification of the epidermal growth factor

receptor (EGFR) in breast cancer, significant progress has been made in our
understanding of the EGFR
signaling pathway and its role in
breast
and

cancer

tumorigenesis

progression

(8).

The

activation of the EGFR pathway
may occur through different
growth factor ligands that bind
to the receptor to induce the
downstream activation of key
regulators
proliferation,

of

cell

growth,

invasion,

ILLUSTRATION 1.2 EPIDERMAL
and FACTOR RECEPTOR SIGNALING

GROWTH

The process of EGF-EGFR and EGFR-EGFR
interaction activates the PI3K/AKT and MAPK
MAPK
signaling
pathways signaling pathways which promote malignant
behavior critical to breast cancer progression.
activated by EGFR promotes
metastasis. The PI3K/AKT and

the progression of breast cancer (illustration 1.2) (9). There are several mechanisms by
which EGFR-mediated tumorigenesis and metastasis can occur including, EGFR gene
amplification, heterodimerization with HER2, and activating mutations, in breast cancer.
Greater than 50% of breast tumors have EGFR amplification, and EGFR has been
2

shown to contribute to the invasiveness of breast cancers and the stem cell phenotype
in breast cancer (10). In the basal-like breast cancer subtype, greater than 50% of
tumors have an overexpression of EGFR (10). Highly aggressive triple-negative breast
cancer (TNBC) and inflammatory breast cancer (IBC) subtypes, characterized by
advanced and less-differentiated histological features associated with a poorer
prognosis, have an overexpression of EGFR in approximately 30 to 50% of tumors (9,
11). Although it is unknown whether EGFR is a predictive marker for TNBC or IBC,
EGFR expression levels are being utilized in treatment studies for patient selection (9),
and EGFR-targeted therapies, lapatinib, erlotinib, and panitumumab, are currently
being exploited in TNBC and IBC (12, 13).

1.3

TRIPLE-NEGATIVE BREAST CANCER
TNBC is an aggressive disease that is commonly diagnosed in younger women

between the ages of 30-40 years, and has a high tendency to develop resistance to
standard chemotherapy and metastasize (14). TNBC makes up about 30% of all breast
cancers diagnosed, and about 40% of the basal-like subtype. Based on the intrinsic
gene expression profile described by Bertucci F.et al., approximately 80% of TNBC
tumors are considered to be basal tumors (15). Both TNBC and basal tumors are
described as having genetic mutations in DNA repair proteins such as, P53, and
BRCA1, and amplification of oncogenes, c-myc, and EGFR (16). Although there is an
overlap between TNBC and basal tumors in gene expression profiles, there is
controversy surrounding the concept that all TNBC tumors are basal tumors.
Histoclinical and molecular differences were detected between basal and non-basal
TNBCs but not between TNBC and non-TNBC basal tumors, which implies TNBC
3

tumors to have a higher degree of heterogeneity than basal tumors. In a gene
expression profiling study conducted by Lehmann B.D. et al, it was observed that
TNBC can be classified based on transcriptional profiles described in the TNBC
subtypes: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal
(M), mesenchymal stem-like (MSL), luminal androgen receptor (LAR), and unstable
(UNS) (17). Masuda H. et al. predicted the BL1 and MSL TNBC subtypes to be the
predominant subtypes in IBC because of the highly aggressive gene expression
profiles inclusive of increased cell proliferative markers (i.e. Ki67), and EMT markers
(17). Not only did both studies confirm the heterogeneity of TNBC but they also
confirmed gene expression linked with an inflammatory response. Indeed, a signature
of transforming growth factor β (TGFβ) activation was identified in the M and MSL
subtypes, while the expression of growth factor signaling molecules including EGFR
was up-regulated in the BL2 and MSL subtypes (12). These findings confirm the TNBC
subtype to be enriched with an inflammatory and metastatic gene expression profiles
which includes BMP2 and ALDH1 mesenchymal stem cell markers. (12).
Metastasis occurs in a higher proportion of TNBC patients than ER+/HER2+
breast cancer patients, at approximately 33% and 20%, respectively (18). Unlike
luminal and HER2-positive breast cancers, which express ER and HER2, TNBC lacks
clinically-validated, markers and targeted therapeutics. Depending upon tumor stage,
size, grade, and the presence of invasive disease at diagnosis, TNBC patients may
receive a treatment regimen including neoadjuvant chemotherapy, surgery, and
adjuvant chemotherapy and radiation therapy (4). Initially, TNBC tumors are sensitive
to chemotherapy and radiation; however, they eventually develop resistance to
treatment resulting in locoregional or distant recurrence.
4

Patients with EGFR-positive TNBC are associated with a poor response to
chemotherapy alone (19). To address this issue, there have been a number of studies
that investigated a combination approach of targeting EGFR with systemic therapy to
delay TNBC progression (20). In a clinical phase II study for patients with late-stage
metastatic TNBC treated with cetuximab alone or in combination with carboplatin
resulted in a higher response rate in those that received combination treatment.
Regardless of this difference,

a majority of patients had activated EGFR pathway

following treatment suggesting that either cetuximab was not effective or the EGFR
pathway is activated, by another pathway independently of its ligand in these tumors
(21, 22). In a phase II clinical study of panitumumab, a fully humanized EGFR-specific
monoclonal antibody, with anthracycline and taxane-based chemotherapy in TNBC, a
higher response rate and longer progression-free survival was observed (23). Despite
the findings that EGFR-targeted therapy with systemic therapy maybe a more
beneficial therapeutic strategy for TNBC patients, we do not have a clear
understanding of the progression of TNBC. It is likely that breast tumors that do not
respond to EGFR-targeted therapy may benefit from other targeted therapy. In light of
the recent discovery that TNBC heterogeneity can be classified based on molecularly
defined subtypes, it is predicted that TNBC tumors belonging to one subtype may be
more responsive to a particular therapy over another (12). For instance, TNBC
expressing mutated BRCA1 or p53 appear to have increased sensitivity to PARP
inhibitors, including those with elevated immune signaling pathways (12). Thus, there
are several clinically-relevant and targetable pathways in certain types of TNBC, which
may help to block progression of the disease and improve survival in TNBC patients.

5

1.4

INFLAMMATORY BREAST CANCER (IBC)
Inflammatory breast cancer (IBC) is an aggressive breast cancer, which makes

up approximately 1-5% of all breast cancers diagnosed in the U.S. It is one of the
deadliest breast cancers, and comprises approximately 8-10% of total breast cancer
mortality rate in the United States (24-26). Despite the fact that IBC is diagnosed as
being a locally advanced and highly invasive breast cancer with inflammatory-like
symptoms including erythema and edema, a molecular mechanism of a physiologic
inflammatory response has not yet been identified in IBC. The clinical manifestations
presented in IBC patients include: erythema, edema, peau d’ orange, and breast
swelling with pain or tenderness (27). In addition, IBC patients may or may not present
with a palpable mass (28). A majority of IBC patients have lymph node metastasis and
30% have distant metastasis at the time of diagnosis (28). Another clinical
manifestation presented in IBC patients is dermal lymphatic tumor emboli, which is
identified by a skin-punch biopsy (29). The current treatment strategy for IBC is a
multimodality approach, which includes pre-operative standard chemotherapy and
radiation therapy, surgery and adjuvant therapy, inclusive of hormone-targeted therapy
(4). Treatment with adjuvant or neoadjuvant hormone receptor therapy, such as
trastuzumab or tamoxifen, is provided to patients with IBC tumors that express HER2
or ER, respectively. Although some IBC tumors respond to current treatment, there is
the dilemma of local and distant recurrence, which needs to be addressed by
investigating molecular targeted therapies (30).
As represented in about 30% of IBC, the overexpression of EGFR is associated
with high risk of recurrence and low 5-year overall survival (9, 31). The use of EGFR
6

inhibitors has been explored in clinical trials as potential therapeutic strategies for IBC
(9). Lapatinib, an EGFR/HER2 dual-kinase inhibitor, was shown to improve clinical
response in a phase II clinical trial in combination with paclitaxel in IBC patients (29,
32). On the otherhand, with about 30-40% of IBC tumors being triple-negative, the
dual-kinase inhibition of EGFR and HER2 is not likely to be a suitable approach for all
IBC cases. In fact, one study revealed a HER2-dependency for lapatinib in metastatic
breast cancer (17, 33). As a consequence of these findings, selective EGFR inhibitors,
such as erlotinib, have become a major focus for the clinical treatment of IBC. The preclinical studies of selective EGFR inhibitor erlotinib demonstrated suppression of IBC
tumorigenicity and metastasis, but in a clinical trial erlotinib treatment had a low impact
on the outcome of advanced breast cancer patients (9, 34). As a result of the
confounding results for HER2 and EGFR-targeted therapies presented in pre-clinical
and clinical-based studies, there is still a need to define molecular drivers of IBC
progression and metastasis.

1.5

EPITHELIAL TO MESENCHYMAL TRANSITION
A cellular process often associated with breast cancer ‘aggressiveness’ is

epithelial to mesenchymal transition (EMT). EMT is a reversible process that takes
place during embryonic development in which cells acquire specific molecular and
cellular features to facilitate their transition between epithelial and mesenchymal
phases (35). Following EMT, cells are endowed with mesenchymal properties and a
migratory phenotype involving the loss of cell-to-cell and cell-matrix adhesion with a
gain in proteolytic activity. In addition to the loss of cell adhesive properties, there is a

7

remodeling of the cytoskeleton during cellular movement, a critical event for
gastrulation
during
embryonic
development
(36).
Althou
gh EMT is a
ILLUSTRATION 1.5 THE INTRINSIC AND EMT-INDUCED CSC WITH
METASTATIC POTENTIAL

normal
process
which
supports
embryonic
development,
and

Cancer stem cells may be intrinsic or induced by extrinsic components,
such as reactive stromal cells. In the case of an induced phenotype,
epithelial to mesenchymal transition (EMT) enables the cells to
transition to a CSC-like phenotype and acquire metastatic potential.
From ‘A Perspective on Cancer Cell Metastasis’. Christine L. Chaffer
and Robert A. Weinberg. Science 25 March 2011:331 (6024), 15591564. [DOI:10.1126/science.1203543. Reprinted with permission from
AAAS.

tissue

repair, EMT can aberrantly occur in cancer cells in adult breast tissue (35). It is
proposed that EMT contributes to cancer based on the concordance between the
mesenchymal phenotype and the characteristics required for cancer cell metastasis.
Breast cancer cells undergo molecular and cellular changes during EMT that enhance
cell migratory and invasive capacity, contributing to a metastatic phenotype (35).
Remarkably, EMT observed in both carcinogenesis and embryonic development is
mediated by similar signaling pathways (36). EMT cellular changes are orchestrated by
the release of secreted signals, such as TGF-β and WNTs, from stromal tissues which
act on nearby epithelial cells (37). These signals mediate the upregulation of
8

mesenchymal markers, fibronectin and vimentin, N-cadherin, and transcription factors,
SNAIL, TWIST, SLUG, and ZEB1, in tumor cells. Mesenchymal transcription factors
suppress the epithelial phenotype and cell-to-cell adhesion through the downregulation
of epithelial protein E-cadherin (38). The EMT-induced upregulation of mesenchymal
markers and downregulation of E-cadherin allows cells to acquire an invasive
phenotype demonstrated in an in vitro 2D culture and three-dimensional (3D) basement
membrane extract (BME)/Matrigel assay (39) . In addition to the acquisition of an
invasive phenotype, there is evidence that breast cancer cells, which undergo EMT, are
endowed with stem cell characteristics (40). EMT can serve as a prerequisite for the
acquisition of CSC-like traits within a cancer cell subpopulation, resulting in an
increased metastatic potential of these subpopulation of cancer cells (illustration 1.5).
It is this subpopulation of cancer cells that must be targeted to block metastasis.

1.6

C ANCER STEM-LIKE CELLS
Cancer stem-like cells (CSCs) are characterized as a subpopulation of cancer

cells endowed with properties similar to that of normal stem cells such as the ability to
self-renew, migrate, invade, evade apoptosis, and give rise to a heterogeneous cell
population which drives recurrence and metastasis (41). Studies imply a role for CSCs
in the resistance to therapy and progression of breast cancer, but how CSCs contribute
to these events is not entirely clear (42). The ability to self-renew is a critical feature of
CSCs and normal stem cells (illustration 1.6) and can be partially demonstrated by an
in vitro mammosphere assay in which clusters of breast cancer stem cells can
proliferate and survive under non-adherent non-differentiating culture conditions (43).
In addition to the mammosphere assay as a surrogate assay for studying the CSC
9

population, several stem
cell marker studies have
been conducted to try to
identify and enrich for
CSCs in breast cancer
(44-47). The
CD44+/CD24- cell
population was identified
as a CSC population
that promotes
metastasis of breast
cancer (44). It is wellestablished that the
basal-like subtype of

ILLUSTRATION 1.6 THE DIFFERENTIATION OF
NORMAL AND CANCER STEM CELLS
In normal tissues, stem cells self-renew and give rise to
committed progenitor cells which eventually differentiate.
Progenitor cells have the capability to dedifferentiate under
the appropriate conditions. In opposition to normal stem
cells, cancer stem cells have an enhanced ability to
transdifferentiate from the non-stem cell to stem cell
phenotype.

breast cancers have derived or have acquired stem cell-like properties during
transformation (48). Cancer stem cells originating from the basal lineage express cell
surface molecules such as the hyaluronan receptor CD44 and have downregulated
heat stable antigen CD24. The expression of CD44 has been linked to the epithelial-tomesenchymal transition (EMT) phenotype by which ectopic expression of CD44 in
normal human mammary cells can facilitate invasion, metastasis, and drug resistance
(49). From a biological perspective, a single-cell isolation from the cell lineage lin/CD24-/CD44+ breast cancer stem cell population can generate new tumors in
immunocompromised mice, supporting a tumorigenic function of the CD44+CD24subpopulation (13). Although the CD44 and CD24 markers may serve as a positive
10

indicator of stem-like characteristics in some breast tumors, CD44 and CD24 may not
be expressed in all breast tumors (42).
In addition to the CD44 and CD24 markers, Aldefluor dehydrogenase 1 (ALDH1)
is a putative stem cell marker associated with poorly differentiated basal-like breast
cancers and resistance to therapy (42). As an enzyme that oxidizes intracellular
aldehydes, it is thought that the activity of ALDH1 may play a role in the early
differentiation of stem cells (13). The expression of ALDH1 was found to be
upregulated in several types of carcinomas including malignant breast tissue (13, 50). It
was also noted as a predictor for metastasis in IBC patients (42). Recently, it was found
that a rare subpopulation of cells within the CSC population, termed side population or
SP cells, have the ability to export a fluorescent dye Hoescht 33342 (46). Cells with a
SP phenotype also have stem cell like characteristics including mammosphere
formation capability, and the ability to initiate tumor formation in an in vivo mouse
model. As one particular signaling pathway that promotes breast cancer progression,
the inhibition of the PI3K/mTOR pathway led to a reduction in the SP cells. Another
CSC marker identified as a potential marker for breast cancer stem cells is the
ganglioside GD2 marker. Higher expression of GD2 level was observed in the more
aggressive basal-like breast cancer cells, which included several TNBC cell lines. The
GD2+ cell population in breast cancer cells demonstrated a CSC phenotype compared
with GD2- cell population (47). As poorly differentiated breast cancers, IBC and TNBC
are enriched with CSCs potentially driven by clinically-relevant molecular targets. As
new evidence emerges supporting the concept of CSCs in the progression of breast
cancer, there is growing interest in the tumor microenvironment and inflammatory
signaling pathways and how they regulate breast CSCs.
11

1.7

CYCLOOXYGENASE-2 (COX-2)
Inflammation plays a critical role in the progression of breast cancer; however,

the mechanisms are not clearly defined. There is evidence that inflammatory breast
cancer is associated with inflammatory-like symptoms and activation of inflammatory
response pathways (51). There are several prospective targets in IBC linked with
inflammation. As an inflammatory response molecule and transcription factor, NFkappa B induces the expression of inflammatory response genes which can facilitate
breast tumor progression, including the cyclooxygenase-2 (COX-2) gene (52).
Activation of NF-kappa B is elevated in the basal-like breast cancer subtype which
includes the EGFR-overexpressing and ER-negative breast cancers (52). In an
investigation of inflammatory response genes in IBC, one study found that about 60%
of NF-kappa B-related genes were up-regulated in IBC tumors compared with non-IBC
tumors (53). Interestingly, PTGS2 (COX-2 gene) was among one of the genes
upregulated by NF-kappa, which plays a critical role in cell proliferation, angiogenesis,
and metastasis (53).
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Unlike COX-1, which is constitutively expressed in all tissues to maintain normal
tissue homeostasis,
COX-2 expression is
undetectable in most
tissues with the
exception of immune
cells, vascular
endothelium, and
synovial

ILLUSTRATION 1.7 CROSS-TALK BETWEEN EGFR AND
fibroblasts.COX-2 is up- COX-2
Stimulation of the EGFR pathway via PGs can activate the
translocation of ERK1/2 to the nucleus where expressions of its
aberrant conditions
target genes, including PTGS2, are up-regulated. Erlotinib or
celecoxib can block the overproduction of COX-2 metabolites,
within tissues displaying PGE and PGF , and thereby, inhibit EGFR/COX-2-mediated
2
2α
cell proliferation, EMT, invasion and CSC phenotype.
inflammation, such as in
regulated under

arthritic joints (54). Upon up-regulation of its expression and activation by inflammatory
cytokines or induction via hypoxic conditions (55), COX-2 catalyzes the conversion of
arachidonic acid to PGs, including its major products, PGE2 and PGF2α (54). In addition
to its role in maintaining normal tissue homeostasis, PGE2 and PGF2α have a protumorigenic effect in contrast to other PGs produced by COX-2 (13). In tumors, where
there is a down-regulation of the enzyme 15-hydroxyprostaglandin dehydrogenase (15PGDH) which normally degrades PGE2 to a 15-keto metabolite, there is an
accumulation of the active PGE2 which leads to a pro-tumorigenic effect (13). PGE2
contributes to tumor progression through binding to the EP4 receptor and the
subsequent transactivation of EGFR through the Arrestin/Src complex, leading to
13

activation of the PI3K/AKT pathway. In addition, activation of the MAPK/ERK1/2
pathway can occur as a result of PG-transactivation of the EGFR signaling cascade
(13). Cross-talk between EGFR and COX-2 leads to an overstimulation in cell
proliferation, and promotes EMT, invasion and CSC phenotype in breast cancer cells
(illustration 1.7). The link between PGs and pro-tumorigenic effects revealed COX-2 as
a prospective target for the treatment of inflammatory-associated conditions.
In early studies, COX-2 inhibitors and non-steroidal anti-inflammatory drugs
(NSAIDs) were efficacious in the treatment of rheumatoid arthritis through inhibition of
pain and inflammation.

However, the use of NSAIDs was associated with

gastrointestinal and cardiovascular side effects (56). To minimize the side effects
associated with pan-COX inhibition, selective COX-2 inhibitors, celecoxib and
rofecoxib, were synthesized. These drugs were designed specifically to block the
enzymatic activity of COX-2 by binding to a site that is accessible in COX-2 but not
COX-1 in order to suppress pain and inflammation while minimizing side effects (54).
In patients with familial adenomatous polyposis (FAP), the use of the first FDAapproved selective COX-2 inhibitor, celecoxib, reduced the occurrence of sporadic
colorectal adenomas (57). Although treatment with celecoxib in arthritis and colorectal
cancer has been successful, the therapeutic efficacy of celecoxib in breast cancer
remains to be seen.
Highly invasive and advanced breast cancers including IBC overexpress COX-2
(58). High COX-2 expression in breast cancer prompted investigation of the correlation
between COX-2 expression and the CSC phenotype of breast cancer (58). There is
evidence that suggests that COX-2 can regulate the CSC phenotype of breast cancer
cells, however the mechanism remains unknown (59). The overexpression of COX-2 in
14

a breast cancer cell line or its transient suppression in a TNBC cell line model showed
that COX-2 can regulate the EMT phenotype including the expression of genes
important for motility, invasion, and metastasis (60). COX-2 can mediate the expression
of MMP-2, a molecule critical for cell motility and invasion, but also those critical for
tumor immunosuppression such as IL-10 (61, 62). It was recently found that the
cytokine IL-17 can induce COX-2/PG signaling in cancer cells to indirectly regulate
tumor-associated macrophages (TAMs) to modulate the microenvironment in favor of
an immunosuppressive tumor microenvironment (63). Induction of the COX-2/PG
signaling pathway, via cytokine stimulation, contributes to the progression of breast
cancer by up regulating the aforementioned PI3K/AKT, MAPK, and NFKB downstream
targets. Studies using celecoxib revealed a role for COX-2 in the tumorigenicity of IBC
cells and regulation of breast cancer stem cells (64). By targeting the COX-2
inflammatory pathway, IBC metastasis could be inhibited through the suppression of
inflammatory molecules which may regulate the stem cell phenotype, leading to a novel
treatment strategy for IBC patients (34, 42).
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1.8

NODAL A STEM CELL
REGULATOR AND ITS
ROLE IN BREAST
CANCER

It is thought that cancer
stem cells may arise as a result
of the uncontrolled expression
of molecules that control stem
cell-fate during embryogenesis.
These embryonic stem cell
regulators, which are downregulated in adult tissues, are
aberrantly re-expressed in
tumors.(65). Nodal, an
embryonic morphogen and
regulator of normal mammary
gland development and stem
cells, is down-regulated in adult

ILLUSTRATION 1.8 NODAL SIGNALING IN
BREAST CANCER CELLS
As a member of the TGFβ superfamily, Nodal
binds to the heterodimer ALK type I and II
receptor complex activating SMAD2/3
transcription factors which complex with SMAD4
and translocates to the nucleus to induce Nodal
gene transcription. In the absence of antagonist
Lefty, breast cancer cells have an up-regulated
positive feedback loop for Nodal expression.

tissues but re-expressed in
malignant breast tumors (65, 66). During embryogenesis, the function of Nodal is to
direct meso-endoderm formation and the specification of the left-right axis in germ layer
formation and patterning (67). Nodal is a ligand member of the TGFβ superfamily. The
canonical signaling of Nodal activates the SMAD2/3/4 signaling pathway through
binding to an upstream receptor complex CRIPTO/EGF-CFC/Activin-like type I and II
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receptors. Upon Nodal binding, SMAD2 is phosphorylated and activated to form a
complex with SMAD3/4. The SMAD2/3/4 complex translocates to the nucleus where it
binds with transcription factors, foxh1, Mixer, or P53 to activate the transcription of ld1,
Nodal, and its inhibitor lefty1/2 (67). The absence of the Nodal antagonist lefty1/2 can
induce a positive feedback mechanism for the overexpression of Nodal in breast tumor
cells (illustration 1.8).
Nodal signaling in breast cancer highly complex due to post-transcriptional and
post-translational modifications, and potential interactions with other TGFB ligands,
which can all regulate Nodal signaling (68). In hypoxia-induced breast cancer
progression, Nodal expression in breast cancer cells facilitates angiogenesis and
metastasis (69). Hypoxic or low oxygen conditions can promote the expression of
Nodal and activation of pro-angiogenic pathways critical to breast tumor progression
(69). In breast cancer cells, the HIF1-4 transcription factors are induced under lowoxygen conditions. Through Notch1 stabilization, HIF1 transcription factors are able to
bind to the NDE promoter site on the Nodal gene to activate the transcription of Nodal.
However, the interaction between HIF1 and Notch in transcriptional activation of Nodal
has not been investigated in breast cancer cells (69).
Another study observed Nodal to promote tumorigenesis and metastasis of
breast cancer cells via EMT linked to the activation of the MAPK signaling pathway
(66). This finding suggested that MAPK activation of Nodal via phosphorylation of the
linker region in SMAD2, promotes SMAD2 activation and subsequent binding to
SMAD3/4 and translocation to the nucleus for transcription of Nodal. Activation of the
Nodal signaling pathway can up-regulate mesenchymal markers, down-regulate
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epithelial markers, and increase cell motility and invasion, which are all prerequisites of
breast cancer progression and metastasis (66).

1.9 RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B
It is known that about 70% of advanced breast cancer patients develop
metastases and between 65-75% of patients with metastatic breast cancer develop
bone metastases (70, 71). The occurrence of bone metastasis disrupts normal bone
remodeling, a tightly regulated balance between osteolytic (bone resorption) and
osteoblastic (bone formation) activity, causing skeletal-related events and pain (71).
Uncontrolled regulation of receptor activator of nuclear factor kappa B (RANK), a key
regulator of normal bone
remodeling

and

mammary

gland

development, promotes
metastasis.
RANK
ligand

the

activator

of

and

its

receptor
nuclear

factor kappa B ligand

ILLUSTRATION 1.9 RANKL/RANK AND THE ‘VICIOUS’
(RANKL) play a major CYCLE
osteoclast Tumor cells may release cytokines and growth factors that act
on osteoblasts. The osteoblasts produce RANKL which bind to
differentiation, activation RANK expressed at the surface of osteoclasts and tumor cells.
Tumor cell proliferation occurs in response to growth factors
and
survival. released by osteoclasts.
role

in

RANKL/RANK regulates
lymphogenesis, and mammary gland development. RANKL binds to its cognate
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receptor RANK expressed on mammary epithelial cells. Normal mammary gland
development of lobulo-alveolar structures and lactation morphogenesis are dependent
upon the function of RANKL/RANK signaling and disruption of this signaling either
through deletion of RANKL or RANK can lead to underdeveloped mammary glands
with an inability to secrete milk (72). RANKL expression can be regulated by several
hormones including parathyroid hormone-related protein (PTHrP) and progesterone.
During breast cancer progression, it has been demonstrated that RANK-positive cancer
cells have a higher propensity to metastasize to the bone, an environment enriched
with pro-tumorigenic RANKL, amongst other growth factors and cytokines that can
facilitate the formation of metastasis (71). A model that best describes the tumor- bone
microenvironment interaction is the ‘vicious cycle’ model. During tumor-bone
interaction, tumor cells overstimulate the production of RANKL in osteoblasts through
secreting growth factors and hormones (i.e. PTHrP, and interleukins). The mechanism
of action for RANKL/RANK is initiated as RANKL binds to RANK expressed on the
surface of osteoclasts and breast tumor cells. RANKL-induced osteolytic activity
promotes the proliferation and invasion of tumor cells through the release of tumorpromoting growth factors, cytokines, and bone matrix components (illustration 1.9) (7375).
Tumor-promoting factors, which promote proliferation and invasion, include
matrix metalloproteinases (MMPs), bone morphogenetic proteins (BMPs), and tumor
growth factor β (TGFβ) (71, 74, 76). MMP promoters contain a cis element which can
be bound by the NFκB transcription factor, a downstream molecule activated by
RANKL/RANK signaling (77). The matrix metalloproteinase 1 (MMP1) activity induces
bone matrix degradation as a consequence of bone metastases (78). Under normal
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conditions, BMPs play a role in osteoblast differentiation and positively regulate bone
formation. However, as a result of tumor cells invading the bone microenvironment,
BMPs are able to stimulate the production of pro-osteolytic and osteoblastic factors as
part of the ‘vicious cycle’ (76). In fact, activated BMPs have also been linked with
cancer stem cells based upon their regulation of EMT in breast cancer cells (79). As a
result of RANKL/RANK signaling, another growth factor secreted by osteoclasts and
tumor cells to stimulate tumor proliferation is TGFβ. TGFβ released by activated
osteoclasts can directly bind to its receptor expressed on the surface of tumor cells and
increase production of PTHrP which can act on osteoblasts or stromal cells in
surrounding visceral tissue to stimulate RANKL production and release. This
mechanism of action generates a positive-feedback loop that leads to further cancer
cell growth in bone (80).
The aggressive phenotype promoted by RANKL is dependent upon RANK
expression in tumor cells. Indeed, RANK-expressing breast cancer cells were observed
to undergo EMT (81). Knockdown of RANK expression in an in vivo mouse model had
reduced the tumorigenesis and self-renewal ability of breast cancer cells indicating a
potential role for RANK signaling in the regulation of CSCs (82). In line with the
potential role of RANK in regulating the tumorigenesis and CSC phenotype in breast
cancer, another study demonstrated that overexpression of RANK increased the
CD44+CD24- subpopulation and expression of stem cell markers, SOX2, NANOG and
OCT4 (81).
In maintaining the physiologic balance between RANKL and RANK in the bone
matrix, osteoprotegerin (OPG), expressed by osteoblasts, functions as a soluble decoy
receptor that binds to RANKL, blocking its ability to bind and activate the RANK
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pathway. In breast tumor cells, there is suppression of OPG expression, resulting in an
uncontrolled positive feedback loop for RANKL production and activation of the RANK
pathway (74). As a potential therapeutic strategy to block overstimulated osteolytic
activity and breast tumor progression, a soluble recombinant form of OPG, OPG-Fc,
has been studied in breast cancer. OPG-Fc has demonstrated to reduce bone lytic
disease in breast cancer patients (83). However, due to the potential health risks
associated with the use of OPG-Fc in humans and its short half-life, a fully-humanized
antibody, denosumab, was investigated as a potential treatment for targeting RANKL.
The use of denosumab for osteoporosis treatment has shown efficacy in a phase II
clinical trial of denosumab treatment in post-menopausal women (84). The proven
efficacy of denosumab in reducing osteoporosis led to clinical investigations of
denosumab as a potential therapy for metastatic breast cancer patients. The use of
denosumab demonstrated a reduction in SREs and pain-associated with metastatic
breast cancer in patients (76). More studies are needed to elucidate the mechanism of
RANK in the metastatic phenotype of TNBC cells and whether targeting the stem cell
population can inhibit the progression of TNBC.

1.10 STATEMENT OF PROBLEM
TNBC and IBC are considered to be the most aggressive and poorly
characterized breast cancer subtypes. Their high rate of recurrence and metastasis,
there is an urgent need to identify molecular targets that will help reduce IBC and
TNBC metastasis and improve clinical outcome (9). There is emerging evidence linking
CSCs with IBC and TNBC progression. However, it is unknown which molecular
pathways can be therapeutically exploited to suppress the progression of TNBC and
IBC.
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1.11 HYPOTHESIS
We hypothesize that targeted inhibition of COX-2 and RANK in IBC and TNBC,
respectively, could eradicate CSCs to suppress tumor progression. By targeting COX-2
and RANK, we can help to eliminate breast cancer metastasis, an inevitable and
deadly outcome associated with these aggressive diseases. Our findings will advance
our understanding of how inflammatory mediators, COX-2 and RANK, regulate the
breast cancer progression and unveil novel potential for COX-2 and RANK as
therapeutic targets.
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CHAPTER 2: TARGETING THE RANK PATHWAY AS A
NOVEL THERAPEUTIC APPROACH IN TNBC
2.1 INTRODUCTION
Triple-negative breast cancer (TNBC) accounts for approximately 25-30% of all
breast cancers and is characterized as lacking ER, PR, and HER2 receptors. Although,
TNBC patients are more likely to respond to neoadjuvant chemotherapy compared with
non-TNBC patients, metastasis following treatment is more likely to occur in TNBC
(85). It is thought that breast CSCs contribute to the development of resistance to
standard therapy and subsequent metastasis (86). Studies demonstrated that the
RANKL/RANK pathway can regulate the ‘stemness’ of breast cancer cells via EMT, a
process linked to tumor initiation, progression, and metastasis (81, 82, 87), however, it
is unclear whether targeted inhibition of the RANKL/RANK pathway could eradicate
CSCs in TNBC. Since TNBC cells are enriched with stem-like features and
demonstrate RANKL-stimulated invasion and metastasis, we hypothesized that
suppressing RANK will eradicate CSCs in TNBC. We investigated RANK in TNBC as a
potential prognostic marker and predictor for clinical outcome by using statistical
methods to assess both RANKL and RANK expression in a TNBC patient cohort. In
addition, we investigated the effects of RANK suppression in TNBC cell migration,
invasion, and CSC phenotype.
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2.2 MATERIALS AND METHODS

2.2.1 CDNA MICROARRAY ANALYSIS
We first performed a statistical analysis to compare the gene expression levels
of RANK between three different patient cohorts derived from the MDACC cohort
(n=57) of the GEO database: 1) ER+/HER2- (n= 22), 2) HER2+ (n= 17), and 3) ER/HER2- (n=18; 17/18 negative for PR). The platform used in which samples were
constructed on was the Affymetrix U133a GeneChip. Cases with normalized ESR1
mRNA expression (probe set 205225_at) were defined as ER-positive for ESR1 >
10.18, cases with HER2 (216836_s_at) were considered HER2 amplified for HER2 >
12.54, and cases with PgR (208305_at) > 2.907 were considered PR positive (17). The
probe set for RANK mRNA (TNFRSF11A: 207037_at) was obtained from the ‘gene
card’ website (http://www.genecards.org/). RANK mRNA expression levels were log2
transformed and normalized using MAS5 algorithm and the P-values were calculated
using Wilcoxon test. P > 0.05 was considered to be statistically significant.
2.2.2 CELL LINES AND TISSUE CULTURE REAGENTS
Human TNBC and non-TNBC cell lines (Table 2.1) were screened for
endogenous levels of RANK expression. MDA-MB-231, MDA-MB-468, BT20, BT474,
KPL4 and MCF7 cell lines were maintained in DMEM/F12 Medium (catalog #12634010; Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum
(FBS) (catalog #10438-026; Life Technologies, Grand Island, NY) and 1% antimycoticantibiotic (AA) (catalog #15240-062; Life Technologies, Grand Island, NY), and
SUM149, SUM159 and SUM190 cell lines were maintained in Ham’s F12 Nutrient Mix
(catalog #11765-054; Life Technologies, Grand Island, NY) supplemented with 5%
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FBS, 1% AA, 5 µg/mL insulin (catalog #I9278; Sigma-Aldrich, St.Louis, MO), and 1
µg/mL hydrocortisone (catalog #H0888; Sigma-Aldrich, St. Louis, MO) in a humidified
atmosphere containing 5% CO2 at 37°C. SKBR3 cell line was maintained in McCoy’s
5a (Modified) Medium (catalog #16600-082; Life Technologies, Grand Island, NY)
supplemented with 10% FBS, and 1% AA. HCC70, HCC38, and HCC1954 cell lines
were maintained in RPMI 1640 medium (catalog #11875-119; Life Technologies, Grand
Island, NY) supplemented with 10% FBS and 1% AA.

2.2.3 LENTIVIRAL-BASED EXPRESSION OF RANK SHRNA
To generate MDA-MB-231 cells with stable knockdown of RANK protein, we
produced lentiviral particles from HEK293T cells transfected with the pGIPZ lentiviral
plasmid expressing short-hairpin RNA (shRNA) against RANK (mature anti-sense 3’TATCTTCTTCATTCCAGCT- 5’; mature sense 5’- ATAGAAGAAGTAAGGTCGA-3’) or
a non-silencing sequence (scrambled shRNA) (GE Healthcare, Dharmacon). HEK293T
cells were co-transfected via Lipofectamine (Invitrogen) with lentiviral packaging
vectors DR82, and VSV-G along with the target plasmid (pGIPZ-Scrambled shRNA or
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pGIPZ-RANK shRNA). MDA-MB-231 cells were seeded at 5 x 104 cells/well into a 24well plate 24h prior to infection with lentiviral infected medium. A 5-fold serial dilution
(dilution factors of 5, 25, 125, 625, 3125, 15625) of viral particles diluted 1/10 in serumfree media were used to infect the 231 cells at 5 x 104 cells/well in a 24-well plate and
293T cells were infected in parallel as a control. At 6 hours post-infection, 1 mL of
complete media was added per well. Cells were cultured for 48h prior to observing GFP
expression seen by light microscope.
GFP-positive colonies were counted and the transducing unit per milliliter
(TU/mL) or multiplicity of infection (MOI) was calculated using the following formula:
(average number of GFP-positive colonies calculated for 4 wells) x (dilution factor) x
40. The lowest MOI was 0.17 for the 125-fold dilution factor. The MDA-MB-231 cells
infected at the lowest MOI were treated with selection antibiotic puromycin (1 µg/mL)
and expanded in culture. Following selection for 2 weeks in 1 ug/mL puromycin diluted
in complete media, the MDA-MB-231 cells infected with pGIPZ-Scrambled shRNA, or
RANK shRNA, were screened for RANK protein expression via flow cytometry analysis.
2.2.4 FLOW CYTOMETRY ANALYSIS
To analyze the level of RANK in MDA-MB-231 Scrambled shRNA and MDA-MB231 RANK shRNA cells, we stained for the following: DAPI (cell viability), APC + IgG1
(negative control), RANK (APC + N2-B10) (Table 2.2). MDA-MB-231 parental cells
were stained as a control only.
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Cells were blocked in FACS blocking buffer (3-5% goat serum + 0.005% sodium azide
+ PBS) for 20 minutes at 4°C with rotation then spun down at 4°C for 4 minutes at 4 x
103 rpm. Cells were re-suspended in FACS buffer (2% fetal bovine serum + 0.005%
sodium azide + PBS) with primary RANK antibody (N2-B10) or purified mouse IgG1
isotype antibody and incubated under the same conditions as in the blocking step.
Cells were washed 2X with FACS buffer prior to incubation with the secondary antibody
(APC) for 30 minutes. For the final wash step, cells were washed 2X with FACS buffer
prior to re-suspension in 1 mL FACS buffer, and analyzed using Gallios flow cytometry
instrument (MDACC Flow Cytometry Core Facility). Histograms were generated using
FlowJo_V10 software (figure 1).
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2.2.5 CELL MIGRATION AND INVASION ASSAYS
MDA-MB-231 scrambled shRNA and RANK shRNA cells were serum starved for
24 hours prior to stimulation with 25 ng/mL human soluble RANKL (product #R138;
Leinco Technologies, Inc. St. Louis, MO) for 24 hours. For Boyden chamber trans-well
migration assay (n=3), 1.5 × 105 cells in serum-free medium were layered in the top
chamber of 24-well trans-well plates with serum-free media containing RANKL (25
ng/mL) in the lower chamber and incubated at 37°C for 6 hours. Cells in the top
chamber (non-migrated) were removed, and cells in the bottom chamber (migrated)
were fixed with 0.1% crystal violet/20% methanol solution. For the invasion assay
(n=3), 1.5 × 105 cells were plated in serum-free medium in the upper chamber of a
Boyden chamber coated with BD Matrigel Basement Membrane Matrix Growth Factor
Reduced Phenol Red Free (catalog #356231; BD Biosciences) with serum-free media
containing RANKL (25 ng/mL) in the lower chamber. Twenty-four hours later, noninvading cells were removed from the upper chamber, and the underside membranes
were fixed and stained as above in the cell migration assay. Migrated and invaded cells
were quantitated by dissolving stained cells in a solution of 4% sodium deoxycholate
and performing colorimetric reading of optical density at 595 nm. Results were
analyzed using unpaired Student’s t-test with a *P value < 0.05 considered significant.
2.2.6 MAMMOSPHERE ASSAY
MDA-MB-231 scrambled shRNA and RANK shRNA cells were plated into an
ultra-low attachment 6-well plate at a density of 5 × 103 cells/well containing
Mammocult Basal Medium (catalog #05621; STEMCELL Technologies, Inc.)
supplemented with 1% Proliferation Supplement (catalog #5622; STEMCELL
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Technologies, Inc.), 2 µg/mL heparin (catalog #07980; STEMCELL Technologies, Inc.),
and 0.12 µg/mL hydrocortisone (catalog #07904; STEMCELL Technologies, Inc.). On
day 5 following incubation, cells from primary mammospheres (P0) were counted and
re-plated for secondary mammosphere (P1) formation. Under both primary and
secondary

mammosphere

conditions,

each

group

was

tested

in

triplicate.

Mammospheres were quantitated on day 5 by staining with MTT reagent (0.4 mg/mL)
for 2 hours and enumerated using GelCount software (Oxford Optronix). Results were
analyzed using unpaired Student’s t-test with a *P value < 0.05 considered statistically
significant.
2.2.7 HUMAN STEM CELL RT2 PCR ARRAY ANALYSIS
Using the human stem cell RT2 PCR array (catalog #PAHS405Z; Qiagen) we
analyzed the gene expression levels of several stem cell markers in MDA-MB-231
scrambled shRNA and RANK shRNA cells. We purified total RNA from each cell line
using the RNeasy Mini prep kit (catalog #74104; Qiagen). The total RNA samples were
reverse transcribed to cDNA using the RT2 First-strand Kit (catalog #330401; Qiagen),
followed by mixing of the synthesized cDNA with the RT2 SYBR Green Mastermix
(catalog #330513; Qiagen) then samples were aliquoted (25 µL/well) into the human
stem cell PCR array 96-well assay plate. The 96-well assay plate included 84 wells
containing primers specific for 84 genes of interest (GOI) and the remaining 12 wells
were control wells including 5 wells for housekeeping genes, 3 wells for reversetranscription controls, and 1 well for control DNA genomic contamination, and 3 wells
for positive PCR controls (Table 2.3).

29

The 96-well plate reactions were generated using a real-time PCR cycler (Bio-Rad CFX
96 model) with cycling conditions compatible with the Bio-Rad CFX96 cycler (Table
2.4)
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The results were analyzed using the CT method available through the SABiosciences
PCR data array analysis Web Portal. The CT value for each reaction was determined
as < 35 or > 35 in which the < 35 values were reported as negative. To normalize the
CT value for each gene of interest (GOI) to the average housekeeping genes the
following formula was used: CT = CT GOI – CT AVG HKG.
2.2.8 CORRELATIVE ANALYSIS OF RANK, RANKL, AND ALDH1 EXPRESSION WITH
CLINICAL OUTCOME IN TNBC
We performed an analysis to correlate the expression of human RANK with
overall survival and time to first metastases in TNBC patients. Core samples (n = 96)
from formalin-fixed paraffin-embedded (FFPE) MDACC TNBC patient tumors were
constructed on TMAs (88) and stained by immunohistochemistry (IHC) with anti-human
RANK (N-1H8 or N2-B10; Amgen, Inc., Seattle, WA) and RANKL (M366; Amgen, Inc.,
Seattle, WA) monoclonal antibodies as described in (89), and interpreted and scored
by pathologist D.B. blinded to clinical characteristics and outcome.
RANK and RANKL expression was quantitated based on the histoscore (H
score) formula defined as the sum of intensity (0, 1, 2, 3) x percentage of intensity;
(percentage of 0 intensity ) * 0+ (percentage of 1 intensity) * 1 + (percentage of 2
intensity) * 2 + (percentage of 3 intensity) * 3. H scores range from 0-300 where
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intensity of staining was defined as 0 = negative, 1 = weak, 2 = moderate, 3 = high,
relative to RANK staining in tumor-associated macrophages as an internal control.
Using the median (RANK H score = 10) as the cut-off value, RANK IHC staining
results were categorically defined as: high RANK (H score > or = 10) or low RANK (H
score < 10), and clinicopathological parameters: age (median = 50 years), race, tumor
size,

lymph

nodes,

pathological

stage

(pStage),

nuclear

grade

(NG),

and

lymphovascular invasion (LVI), were tabulated and compared between the high RANK
and low RANK groups using the Fisher’s exact test; P < 0.05 statistically significant.
The Kaplan-Meier survival curve analysis was used to estimate the survival of each
group: high RANK (n = 49) and low RANK (n= 47) and were compared using a log-rank
test; P < 0.05 statistically significant. SPSS statistic software (version 20.00; IBM
corporation, Armonk, NY) was used to estimate the association between each RANK
group and ‘Overall survival ‘defined as from date of surgery to date of death or loss of
follow-up and ‘Time to first metastases’ defined as from date of surgery to date of first
metastases detected. The median follow-up time was 2025 days (range 346-5906).
TNBC patient tumors (n=91) were stratified as RANK positive (RANK >0; n=66)
or RANK negative (RANK =0; n=25). A correlative analysis was performed for RANKL
expression with clinicopathological parameters (appendix D) and statistically analyzed
using fisher’s exact test, P-value > 0.05 considered to be significant. Kaplan-Meier
curves for OS and RFS was performed for both RANK positive and RANK negative
cohorts, and a log-rank test was performed to determine the p-value. SPSS statistic
software (version 20.00; IBM corporation, Armonk, NY) was used to estimate the
association between RANKL > 0 and RANKL = 0 in both RANK cohorts.
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IHC staining of ALDH1 was performed on proximal TMA sections of TNBC tumor
specimens (MDACC Histology Core Facility) as described in (42) and interpreted and
scored by pathologist S.K. blinded to clinical characteristics and outcome. ALDH1
scores were determined based on the average percentage of intensity in either tumor
cells and/or stroma.
2.2.9 STATISTICAL ANALYSIS FOR CLINICAL AND NON-CLINICAL DATA
Patients with histologically defined TNBC were divided into two groups based on
H scores: RANK positive (H score > 0) and RANK negative group (H score =0).
Baseline patients’ characteristics include age, race, menopausal status, pathological
stage, nuclear grade, lymphovascular invasion, and estrogen receptor expression and
they were tabulated. For the comparison of continuous variables, we used Wilcoxon
rank sum test. Associations between two groups were assessed by using Fisher’s
exact test. Overall Survival (OS) was defined from the date of surgery to that of death
and Recurrence Free Survival (RFS) was defined from the date of surgery to that of
first local or distant metastasis or lost follow-up whichever comes earlier. Patients who
died before having a recurrence event were censored at the date of death. The KaplanMeier survival curves were used to estimate the survival of each group and two groups
were compared by using log-rank test. Chi-square test or Fisher’s exact test was used
to assess the correlation among categorical variables depending on their expected
values. Multivariate Cox proportional hazard models were used to evaluate the
association of covariates with survival.

Covariates with p-value < 0.3 in univariate

analysis were included in multivariate analysis.
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A p-value < 0.05 was considered statistically significant. All statistical analyses
were performed by STATA version 13 (STATA Corp, College Station, TX). This study
was approved by the Internal Review Board at the University of Texas MD Anderson
Cancer Center.
For cDNA microarray analysis, cases were normalized with MAS5 algorithm and
RANK mRNA gene expression was log2 converted and the P-value was calculated by
the wilcoxon test.

For all other in vitro studies, student t-test was performed to

determine the p-value. P-value > 0.05 considered significant.
For all other data, results were presented as mean ± SD except where otherwise
stated. When two groups were compared, Student’s t-test was used (P < 0.05 was
considered significant).
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2.3 RESULTS
2.3.1 RANK IS HIGHLY EXPRESSED IN HUMAN TNBC PRIMARY TUMORS
Since the study of RANK expression in breast tumors has resulted in
discrepancies in RANK expression in breast tumors and its prognostic value, and has
not yet been studied in TN breast tumors (90), we evaluated the clinical relevance of
RANK expression in TNBC by first interrogating the expression of RANK and RANKL
amongst TNBC patients. We analyzed the level of RANK mRNA expression in patient
tumors from the MDACC IBC data set. ER-/HER2- (n=18) was compared with other
breast cancer cohorts, ER+/HER2- (n=22) and HER2+ (n=17) by statistical analysis of
patient tumor-derived RANK mRNA constructed on an Affymetrix U133a GeneChip
array. We found the ER-/HER2- cohort to have a statistically significant higher level of
RANK expression compared to the ER+/HER2- breast tumor cohort (P = 0.034) while
there was not a statistically significant difference in RANK mRNA expression between
ER+/HER2- and HER2+ cohorts (Figure 2.1). In addition, we looked at RANK mRNA
expression in TNBC and non-TNBC primary tumors and observed RANK mRNA levels
to be higher in the TNBC compared to non-TNBC tumors (Figure 2.2).
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Figure 2.1 RANK mRNA expression is significantly higher in ER-/HER2- breast
tumors than ER+/HER2- tumors. We analyzed RANK gene expression using an
Affymetrix U133a GeneChip array containing mRNA from breast tumors taken from the
following cohorts: ER-/HER2- (n= 18) cohort, HER2+ (n=17), and ER+/HER2- (n=22).
Results were normalized with MAS5 algorithm and log2 transformed and p-values were
calculated by Wilcoxon test (P-value = 0.034).
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Figure 2.2 RANK mRNA expression is significantly higher in TNBC compared to
non-TNBC tumors. We analyzed RANK gene expression using an Affymetrix U133a
GeneChip array containing mRNA from breast tumors (n=57) taken from the following
cohorts: TNBC (n=17) and non-TNBC (n=40). Results were normalized with MAS5
algorithm and log2 transformed and p-values were calculated by Wilcoxon test (P-value
= 0.045).
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2.3.2 RANKL IS A PREDICTOR OF WORSE CLINICAL OUTCOME IN RANK-POSITIVE TNBC
Previous retrospective studies have shown that RANK expression can predict
the occurrence of skeletal-related events (SREs), bone disease progression, and death
(75). As effective RANK signaling requires the presence of RANKL, we sought to find
out if associated RANK and RANKL expression in TNBC tumors could better delineate
clinical outcome. TMAs constructed with core biopsies from TNBC patients (n=91) and
tumor-associated macrophages (TAMs) were stained as an internal control for RANK
and RANKL positivity (data not shown) with anti-human RANK monoclonal antibody (N1H8 or N2-B10; Amgen, Inc.) and RANKL antibody (M366; Amgen, Inc.). RANK and
RANKL expression was semi-quantitated by H score method. The cut-off value for
positive RANKL/RANK was H score > 0. Based upon our initial analysis that a
univariate analysis of RANK expression did not correlate with clinicopathological
parameters and was not associated with a lower RFS or OS (data not shown), we
performed statistical analyses for RANKL expression in both RANK negative and
RANK positive cohorts. According to a Fisher’s exact test (P –value > 0.05 significant)
to correlate clinicopathological parameters (age, race, menopause, NG, pStage, and
LVI) in the whole cohort (n=91) (Table 2.5), 55.4% (n=41) of RANKL-negative TNBC
patients correlated with pStage II disease (p-value = 0.551; not significant). There was
a significant correlation between nuclear grade III and RANKL negativity, 94.6% (n=69)
of RANKL negative tumors were nuclear grade III (p-value < 0.01). Lymphovascular
invasion did not significantly correlate with RANKL expression (p-value = 0.705). In a
univariate and multivariate analysis for 5-year recurrence and overall survival in the
RANK positive TNBC cohort (n=66), RANKL expression was found to be an
independent predictor for worse survival outcome (Table 2.6). A Kaplan-Meier survival
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curve analysis was performed to determine if RANKL associated with a poorer relapsefree survival and overall survival. We did not observe RANKL associated with survival
outcome in RANK negative cohort (Figure 2.3), but we did observe RANKL associated
with a worse survival outcome (Figure 2.4).
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Figure 2.3 RANKL expression is not associated with poor clinical outcome in RANK-negative TNBC. Kaplan-Meier curve
analysis of TNBC patients with primary breast tumors negative for RANK expression (RANK = 0) including RANKL positive (n=
16) or negative (n=74) was performed for recurrence-free survival (left), and for overall survival (right). A log-rank test was
performed between RANKL positive and negative groups in each analysis to determine the p-value.
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Figure 2.4 RANKL expression is associated with poor clinical outcome in RANK-positive TNBC. Kaplan-Meier curve analysis of
TNBC patients with primary breast tumors positive for RANK expression (n=66) were stratified as RANKL positive (n=11) or negative
(n=55) was performed for assessment of recurrence-free survival (left) and overall survival (right). A log-rank test was performed
between RANKL positive and negative groups to determine the p-value.
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2.3.3 HUMAN TNBC CELL LINES HAVE HIGHER EXPRESSION OF RANK THAN NON-TNBC
CELL LINES

Based on our clinical findings that RANK expression was higher in the TNBC
cohort compared to non-TNBC, we screened a panel of human TNBC and non-TNBC
cell lines for RANK protein expression by flow cytometry analysis. By immunostaining
of endogenous RANK with an anti-human RANK monoclonal antibody (N2-B10) and
APC secondary antibody, followed by detection using flow cytometry analysis, we
observed higher APC-RANK expression levels in the majority of TNBC cell lines
compared to non-TNBC cell lines (Figure 2.5). We calculated the median difference
between the isotype control peak (red) and APC-RANK peak (blue). We found the
TNBC cell lines to have a higher median difference and averaged median difference
compared to the non-TNBC cell lines (Appendices A and B). The MDA-MB-231 TNBC
cell line had high levels of RANK expression that was comparable to that of other
TNBC cell lines (HCC70, MDA-MB-468, and HCC38). Due to its high tumorigenicity
and metastatic ability, we used the MDA-MB-231 cell line for subsequent experiments
to investigate the role of RANK in TNBC cells. We investigated the effects of RANK
suppression in MDA-MB231 to characterize the role of RANK and determine if RANK is
a potential therapeutic target for inhibiting the progression of TNBC.
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Figure 2.5 RANK expression is higher in TNBC cell lines compared to non-TNBC
cell lines. A panel of human A) TNBC and B) non-TNBC cell lines were screened by
flow cytometry for endogenous RANK expression. Isotype control (red peak), and APCRANK positive (blue peak). Y-axis = Count (number of cells); X-axis = APC-RANK
signal intensity. Flow cytometry results were analyzed by FlowJo version VX software.
The APC positive value medians for TNBC and non-TNBC were calculated and
graphed using Graphpad Prism version 6.01 (boxplot graph).
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2.3.4 SUPPRESSION OF RANK DECREASED MDA-MB-231 CELL MIGRATION AND
INVASION

Evidence suggests RANK/RANKL to promote breast cancer metastasis, but the
role of RANKL/RANK in breast cancer metastasis is not well understood. Using MDAMB-231 cells, we investigated the effects of RANK suppression in TNBC cell migration
and invasion. In consensus with another study conducted by Tang ZN et al. (91), after
we observed suppression of RANK to have little effect on the migration and invasion of
MDA-MB-231 cells in the absence of RANKL-stimulation (data not shown), we prestimulated MDA-MB-231 scrambled shRNA and RANK shRNA cells with 25 ng/mL
human soluble RANKL for 24 hours prior to seeding cells for 6-hour Boyden chamber
transwell cell migration and 24-hour cell invasion assay. We observed MDA-MB-231
RANK shRNA cells to have significantly decreased cell migration (figure 2.6A) and
invasion (figure 2.6B).
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Figure 2.6 Suppression of RANK reduced RANKL-stimulated MDA-MB-231 cell
migration and invasion. MDA-MB-231 scrambled shRNA and MDA-MB-231 RANK
shRNA cells were pre-stimulated with human soluble RANKL (25 ng/mL) for 24 hours
prior to a Boyden chamber transwell cell migration (6-hour) and invasion assay (24hour). A) Cells migrated for 6 hours, B) cells invaded growth factor-reduced Matrigel for
24 hours. Migrated and invaded cells were quantitated by fixing and staining with 0.1%
crystal violet/20% methanol solution followed by resuspension in 4% sodium
deoxycholate and quantification using Perkin-Elmer Microplate reader at 595 nm. *P >
0.01 statistically significant.
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2.3.5 SUPPRESSION OF RANK DECREASED SELF-RENEWAL ABILITY
The RANKL/RANK pathway plays an important role in the progression of breast
cancer, but the CSC phenotype which contributes to the invasiveness of TNBC, had
not been well-studied (91).To determine if RANK can regulate the CSC phenotype, we
performed a mammosphere assay in which MDA-MB-231 RANK shRNA, or MDA-MB231 Scrambled shRNA cells were cultured under low adherence conditions in
mammosphere media. Following a 6-day incubation period, we observed a reduction in
the number of primary mammospheres (P0) formed and the number of secondary
mammospheres (P1) formed which is associated with a reduction in the self-renewal
ability of MDA-MB-231 cells (Figure 2.7).
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Figure 2.7 Mammosphere formation and self-renewal ability of MDA-MB-231 cells
was reduced by the suppression of RANK. MDA-MB-231 scrambled shRNA and
MDA-MB-231 RANK shRNA cells were seeded into ultra-low attachment 6-well plates
in mammosphere media and cultured for 6 days for primary (P0) mammosphere
formation followed by re-plating of cells for secondary (P1) mammosphere formation
(self-renewal ability) for an additional 6 days. P0 and P1 mammospheres were stained
with 5 mg/mL MTT reagent for 1 hour then quantitated by GelCount software. *P < 0.01
statistically significant.
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2.3.6 STEM CELL GENES ARE MODULATED BY THE SUPPRESSION OF RANK IN MDA-MB231 CELLS
Previous studies have found that the RANKL/RANK pathway regulates EMT and
CSC phenotype of breast cancer cells (81, 92). To determine which stem cell pathways
are regulated by RANK in TNBC cells, we analyzed stem cell gene expression levels of
MDA-MB-231 RANK shRNA cells using a human stem cell RT2 PCR array. We
observed several stem cell genes downregulated in MDA-MB-231 RANK shRNA cells
when normalized to the MDA-MB-231 scrambled shRNA cells (Figure 2.8). The top five
stem cells genes that had the greatest reduction in expression based on the foldregulation were: 1) BMP2, 2) CCND2, 3) FOXA2, 4) SOX2, and 5) BMP3 (Table 2.3).
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Figure 2.8 Human stem cell genes in MDA-MB-231 cells are modulated by the suppression of RANK. A qRT PCR array (Qiagen
PAHS405A) was used to analyze stem cell gene expression in MDA-MB-231 RANK shRNA normalized to MDA-MB-231 Scrambled
shRNA. A heat map was generated showing the log 2 fold-change in stem cell gene expression for MDA-MB-231 RANK shRNA
normalized to MDA-MB-231 scrambled shRNA. The negative inverse of the fold-change (data not shown) was calculated to obtain the
fold-regulation and the top 5 stem cell genes of interest were selected based on the greatest magnitude of fold-regulation (Table 2.3).
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2.4 DISCUSSION
TNBC is one of the most aggressive and deadliest breast cancer subtypes
without any clinically-defined molecular targets for treatment. There is a critical need for
finding a therapeutic target to prevent the relapse and progression of TNBC.
RANKL/RANK pathway is critical to the metastasis of breast cancer. Although RANK
expression is associated with increased metastasis and poor prognosis in breast
cancer, RANK has not been investigated in the progression of TNBC. In determining
whether RANK expression is associated with the more aggressive TNBC subtype, we
analyzed the basal levels of RANK gene expression in primary breast tumors
constructed on an Affymetrix cDNA GeneChip array. Stratified by hormone receptor
status, our results indicated RANK expression to be higher in the ER-/HER2- breast
tumors compared to ER+/HER2- breast tumors (Figure 2.1). Despite the significantly
higher RANK gene expression in the ER-/HER2- breast tumors compared to
ER+/HER2- breast tumors, ER-/HER2- breast tumors did not have significantly higher
level of RANK expression compared to the HER2+ breast tumors. When we had
analyzed RANK expression in breast tumors stratified as TNBC or non-TNBC, we
found RANK expression was significantly higher in TNBC tumors (Figure 2.2). This
finding is in concordance with another study conducted by Santini D. et al. in which ERbreast tumors were found to have significantly higher RANK expression compared to
hormone receptor-positive breast tumors (93). Thus, this finding suggests RANK
expression to be elevated in TNBC tumors compared to non-TNBC tumors, and
provides a rationale to investigate RANK protein expression and its prognostic value in
TNBC patient tumors.

53

Generally, the more aggressive breast cancer subtypes are associated with a
poorer prognosis. To investigate whether RANKL or RANK expression in TNBC
associated with a poorer clinical outcome, we analyzed IHC staining of RANK and
RANKL proteins in TNBC TMAs. In the whole cohort of TNBC patients (n=91), we
performed a correlative analysis to look at RANKL expression and clinicopathological
parameters. We found a significant correlation between RANKL negative tumors and
nuclear grade (NG) III clinical factor (Table 2.1). This suggests that in the absence of
RANK expression (n=25), RANKL does not predict an advanced and poorly
differentiated TNBC tumor. In a Kaplan-Meier curve analyses for RANK negative cohort
stratified by RANKL, we observed RANKL did not have an association with the
recurrence-free survival or overall survival in TNBC patients (Figure 2.3). This finding
supports the results of our initial analysis that RANK expression alone, irrespective of
RANKL, is not a predictor of clinical outcome in TNBC patients (data not shown).
Alternatively, we analyzed RANKL expression in the RANK positive cohort (n= 66)
performing univariate and multivariate analyses using clinicopathological parameters
that were obtainable for up to 5 years post-diagnosis. In both analyses, we observed
RANKL positive tumors to be associated with a worse 5-year recurrence and overall
survival compared to RANKL negative tumors (Table 2.2). This suggests RANKL to be
an independent predictive factor for the 5-year recurrence and overall survival in TNBC
patients. In the Kaplan-Meier curve analysis for recurrence-free survival and overall
survival, we observed an association between RANKL positive and a shorter
recurrence-free survival and overall survival (Figure 2.4). In relation to other studies
which have indicated RANK to be associated with a poor breast cancer prognosis (94),
our results indicate RANK expression to be essential for the RANKL association with
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poor prognosis of TNBC. In contrast to our study, Santini D. et al. reported low
expression of RANK in primary breast tumors and concluded RANK to be a predictive
marker for bone metastasis in breast cancer patients (93). The discordance between
our study and the study by Santini D. et al. of RANK expression associated with overall
survival could be explained by the different methods used to define the cut-off for
RANK expression, and the variability in IHC staining of RANK protein, which can result
in detected RANK-positive events in tumor samples across both studies. Owen S. et al.
observed a breast cancer cohort with reduced RANK mRNA expression to have a
significantly poorer overall survival compared to those with higher RANK mRNA
expression (95). In contrast to this, an investigational study of RANK protein in primary
breast tumors found RANK did not correlate with clinical factors while high RANK
expression associated with a poorer outcome compared to low RANK expression (94).
In addition, Park et al. observed RANK protein expression to associate with a poorer
disease-free survival and RANKL to significantly correlate with primary breast tumors
with a lower Ki67 proliferative index (96). In comparison, we also did not observe RANK
to correlate with clinical factors but did find RANKL negativity to correlate with a higher
nuclear grade. We speculate that depending upon the breast tumor cohort, RANK is
associated with a poorer clinical outcome and RANKL is a predictive factor for a
clinically aggressive TN breast tumor in the presence of RANK. This could indicate that
activated RANKL/RANK pathway promotes an aggressive TNBC phenotype and poorer
outcome.
Upon observing an association between the co-expression of RANK and RANKL
and poorer outcome in TNBC patients, we investigated whether endogenous RANK
expression in a TNBC cell line can recapitulate an aggressive behavior in in vitro
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studies. We performed flow cytometry analysis to compare endogenous RANK protein
levels between a panel of TNBC and non-TNBC cell lines. Endogenous RANK protein
expression was observed to be higher in TNBC cell lines compared to non-TNBC cell
lines (Figure 2.5). Interestingly, the TNBC cell line SUM149 was observed to have a
lower amount of RANK protein expression relative to the other TNBC cell lines. Within
the non-TNBC cohort, ER-/HER2+ cell lines SUM190, SKBR3, and HCC1954, were
observed to have relatively higher amount of RANK protein level compared to all other
non-TNBC ER+ cell lines. These results confirm that ER- breast cancer tends to have
higher levels of RANK expression compared to ER+ breast cancers. However, there is
a general consensus that there is discordance in RANK expression in breast tumors
and breast cancer cell lines at the transcriptional and protein level (90, 91). TNBC is a
heterogeneous disease and that RANK expression varies across breast cancer
subtypes as we had observed that not all TNBC cell lines have high RANK expression.
Possible reasons for discordance between the reported RANK expression level in cell
lines may be due to the variation in post-transcriptional regulatory mechanisms and
immunohistochemistry staining for RANK protein (74). Nevertheless, our findings
warrant a comparative study of RANK expression between TNBC molecular subtypes
(BL1, BL2, IM, LAR, M, MSL, and UNS). By applying this strategy, we may be able to
determine if RANK expression in TNBC tumors or cell lines is significantly associated
with a particular TNBC molecular subtype.
To study the biological role of RANK in the invasive and CSC phenotype of
TNBC cells, we knocked down RANK in MDA-MB-231 using a lentiviral-based shRNA
system. We observed the suppression of RANK, following stimulation with and in the
presence of RANKL as a chemo attractant, to significantly reduce MDA-MB-231 cell
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migration and invasion. This result is comparable to what was observed in other studies
of RANKL-stimulated MDA-MB-231 cell migration and invasion (91, 97). Jones D.H. et
al. reported RANKL-independent signaling through CXCR4 chemokine signaling
pathway in MDA-MB-231 cell migration and invasion (97). CXCR4 chemokine receptor
expression is upregulated by the NFkB pathway. Tang Z. et al. reported the inhibition of
Src to abrogate RANKL-stimulated MDA-MB-231 cell migration and invasion, and
concomitantly suppressed downstream activity of ERK1/2, P38, and JNK (91). Other
studies have shown that these same pathways were activated following RANKL
stimulation in ER-negative and ER-positive breast cancer cell lines, SKBR3 and T47D,
respectively (82, 97). Although our in vitro migration and invasion assays confirmed the
suppression of RANK significantly reduced RANKL-stimulated TNBC cell migration and
invasion, we do not know which signaling pathways downstream of RANK mediate
MDA-MB-231 cell migration and invasion. Further studies are required to investigate
potential signaling pathways downstream of RANK, including JNK, P38 MAPK, and the
activation of NFκB, as mediators of TNBC cell migration and invasion.
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Since CSCs are
associated with breast
cancer cell motility and
invasion

and

are

features

of

an

aggressive phenotype,
we

investigated

whether

the

suppression of RANK ILLUSTRATION 2.4 A PROPOSED MODEL FOR
RANKL/RANK-MEDIATED BMP2 SIGNALING IN TNBC
negatively
regulates CELLS
the self-renewal ability RANKL binds to RANK expressed on the surface of TNBC
cells and induces the transcription of BMP2 which then the
of TNBC cells by secreted form binds to its receptor to activate the SMAD1/5/8
signaling cascade to activate transcription of several properforming an in vitro
metastatic and inflammatory genes such as other BMPs,
mammosphere assay. MMPs, and IL-11. This chain of events supports a proliferative
and pro-metastatic state including EMT and CSC phenotype.
In the mammosphere
assay, we observed the knockdown of RANK to significantly reduce primary and
secondary MDA-MB-231 mammospheres. Thus, we concluded RANK to positively
regulate the CSC phenotype of TNBC cells. Our findings are in concordance with other
studies, which demonstrated RANK regulation of breast CSCs in TNBC cells. It was
observed in a study by Pelligrini P. et al. that overexpression of RANK promoted the
repopulation of differentiated breast tumor cells and cancer stem cells in an in vivo
mouse model (98).
To find out if the suppression of RANK modulated stem cell genes in MDA-MB231 cells, we performed a RT2 PCR human stem cell array analysis to compare the
58

expression levels of stem cell genes between MDA-MB-231 RANK shRNA and MDAMB-231 Scrambled shRNA cells. Based on our findings, we concluded RANK regulates
breast CSCs through stem cell genes implicated in cell proliferation and differentiation.
Bone morphogenetic protein 2 (BMP2) had the greatest magnitude in fold-regulation (22.91), followed by CCND2 (-16.28), FOXA2 (-13.55), SOX2 (-11.17) and BMP3 (-8.72).
The bone morphogenetic proteins (BMPs) are growth factors which regulate cell
proliferation and differentiation. BMP2 in particular is considered a mesenchymal stem
cell-specific marker which regulates cell differentiation (12), while BMP3 is an
antagonist for the BMP receptor (99). FOXA2 and SOX2 are both stem cell regulators
involved in cancer metastasis. CCND2 (cyclin D2), a proliferative marker and regulator
for G1/S phase cell cycle transition, can increase malignancy through enrichment of the
stem cell population (100). However, there is no evidence suggesting that RANKL
stimulation of RANK in breast tumor cells regulates the expression of cyclin D2. As
opposed to BMP3, which has anti-tumorigenic effects, BMP2 harbors oncogenic activity
to promote tumor cell invasion and metastasis. In a study by Blake M.L. et al., RANKL
stimulation of MDA-MB-231-RANK cells up-regulated pro-metastatic genes MMPs
(MMP1, 3, 7, and 9) and IL-11 (55). In addition, another study found metastatic genes
up-regulated in a bone-metastatic derivative subpopulation of MDA-MB-231 cells (101).
Transcription factors FOXA2 and SOX2 play a critical role in regulating progenitor cell
development, differentiation, and migration (102). The link between SOX2 and breast
cancer progression is that it’s found to be primarily expressed in early-stage breast
cancers rather than in the later-staged or invasive breast cancers, indicative of a
functional role in tumor initiation (103). The mechanism underlying the dedifferentiation
of breast cancer cells by SOX2 expression is unknown, however, one study indicated
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NFkB to indirectly regulate SOX2 (103). NFkB is a target downstream of the
RANKL/RANK pathway and therefore, it is logical to conclude that the stem cell genes
in the PCR array screen are possibly indirectly modified by the suppression of RANK.
In addition, the methods used to investigate gene expression regulated by RANK,
including stimulation with or without RANKL stimulation, are likely to vary the outcomes
in expression of these stem cell genes. Therefore, our study warrants an investigation
into the modification of stem cell genes (BMP2, BMP3, SOX2, FOXA2, and CCND2) by
RANKL stimulation.
In summary, the observation of higher RANK expression in TNBC tumor
samples merits an investigation into the prognostic value of the RANK pathway in a
clinical cohort of TNBC. Our findings suggest that there is a positive correlation
between RANK and RANKL protein expression which

is associated with poor

prognosis of TNBC patients. Based on in vitro studies, we conclude that targeting the
RANK pathway could be a potential strategy for reducing the progression of TNBC. We
will investigate molecular pathways downstream of RANK, including regulators of the
stem cell phenotype to elucidate the mechanism of TNBC progression through RANKL
stimulation. We will perform experimental and spontaneous metastasis mouse models
using a TNBC cell line expressing luciferase-tagged RANK shRNA in mice, we will
generate experimental and spontaneous metastasis models to monitor the effects of
RANK suppression on TNBC metastasis and expression of metastatic and stem cell
markers.
From a clinical perspective, targeting RANKL to block RANKL/RANK activity in
TNBC is a suitable approach because there is evidence of improved breast cancer
patient survival and reduced bone metastases following denosumab treatment.
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A

Phase II Clinical study in ER-positive breast cancer patients, in which denosumab has
already been described to reduce bone metastases, we will investigate the effects of
denosumab on the presence of CTCs and DTCs. Since the use of denosumab has not
been studied in a TNBC patient population, we may also conduct a pilot study in TNBC
patients treated with neoadjuvant denosumab in which the presence of CTCs and
DTCs will be evaluated before and after denosumab treatment.

CHAPTER 3: COX-2 PROMOTES TUMORIGENESIS OF IBC
THROUGH THE REGULATION OF NODAL
3.1 INTRODUCTION

IBC is one of the most aggressive breast cancers accounting for approximately
8-10% of all breast cancer-related deaths in the U.S. Despite the fact that IBC is a
locally advanced breast cancer associated with inflammatory-like symptoms, a
physiologic mechanism of inflammatory response has not yet been found in IBC. There
is evidence that implicates a role or COX-2 in enrichment of CSCs in breast cancer.
However, the mechanism of COX-2-regulated breast CSCs is not clearly defined.
Suppression of the CSC phenotype in IBC may have anti-tumorigenic and antimetastatic potential. It was reported in IBC that the EGFR pathway promotes EMT, a
requisite of breast cancer metastasis and an observed invasive-like phenotype
associated with CSCs. In this study, we not only observed a positive correlation
between EGFR and COX-2 expression in IBC tumors, but we found COX-2 to regulate
EMT in IBC cells. Furthermore, in our investigation, treatment with COX-2 selective
inhibitor, celecoxib, downregulated Nodal expression, a potential stem cell marker
regulated by COX-2. Thus, we evaluated the Nodal stem cell pathway as a potential
target for eradicating CSCs in IBC.
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3.2 MATERIALS AND METHODS

3.2.1 CDNA MICROARRAY ANALYSIS
For this study, we used an Affymetrix U133a GeneChip array constructed with
cDNA derived from human IBC (n = 25) and non-IBC (n = 57) tumor specimens from
The University of Texas MD Anderson Cancer Center IBC database. Gene expression
obtained from the microarrays was normalized with the MAS5 algorithm, meancentered to 600 and log 2-transformed. Statistical analyses were performed by using
BRB-ArrayTools version 3.9.0 alpha (http://linus.nci.nih.gov/BRB-ArrayTools.html) and
R statistical software version 3.0.0 (http://www.r-project.org/). The correlation between
the mRNA expression levels of EGFR (211551_at) and COX-2 (204748_at) was
analyzed using the Spearman’s rank correlation coefficient analysis.
3.2.2 CELL LINES AND TISSUE CULTURE REAGENTS
Human non-IBC breast cancer cell lines, BT-474, SK-BR-3, MDA-MB-231,
purchased from American Type Culture Collection, were grown in Dulbecco’s modified
Eagle’s medium/F12 medium supplemented with 10% FBS (GIBCO/BRL) in a
humidified atmosphere containing 5% CO2 at 37°C. IBC cell lines, SUM149 and
SUM190, were purchased from Asterand (Detroit, MI) and were grown in Ham’s F12
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medium supplemented with 5% FBS, 5 μg/mL insulin, 1 μg/mL hydrocortisone, and 1%
antibiotic-antimycotic. The human IBC cell line KPL-4 (104) was kindly provided by Dr.
Junichi Kurebayashi (Kawasaki Medical School, Japan) and maintained in Dulbecco’s
modified Eagle’s medium/F12 medium supplemented with 10% FBS and 1% antibioticantimycotic. Non-IBC and IBC human breast cancer cell lines were validated using a
short term tandem repeat method based on a primer extension to detect single base
derivations in October 2010, and July 2013, respectively, by the Characterized Cell
Line Core Facility at M.D. Anderson Cancer Center. Cells used for experiments were
grown in culture for no longer than 2 months. All cell lines were confirmed to be
mycoplasma free using a MycoAlert Mycoplasma Detection Kit (Lonza Cologne AG).
For prostaglandin (PG) treatment, cells were serum-starved for 24 hours prior to adding
PGE2 (catalog #14010; Cayman Chemical) or PGF2α (catalog #16010; Cayman
Chemical) was added to the cells cultured in serum-free medium. Celecoxib (Selleck
Chemicals,

Houston,

TX)

was

reconstituted

in

dimethyl

sulfoxide

(DMSO).

Recombinant human Nodal (R&D Systems, Inc., Minneapolis, MN) was reconstituted in
4 mM HCl and 0.1% bovine serum albumin solution.
3.2.3 WESTERN BLOT ANALYSIS
Cell lysates were prepared as follows: 1) Cells were washed 1X with cold 1X
PBS, 2) On ice, 1 mL of cold 1X PBS was added/plate or well and cells were scraped
with a cell lifter and collected in 1.5 mL Eppendorf tubes, 3) cells were centrifuged for 4
minutes at 4°C at 4 x 103 rpm, 4) cell pellets were lysed on ice in 30-40 uL 1X RIPA cell
lysis buffer containing 1:100 phosphatase and protease inhibitors, and finally, cell
lysates were cleared by centrifugation for 30 minutes at 4°C at maximum speed (13.2 x
63

103 rpm). See ‘Bradford Protein Assay’ methods section for determination of total
protein concentrations.
Western blot analysis was performed as previously described (105) using the
following antibodies (table 3). anti-EGFR (catalog # sc-03; Santa Cruz Biotechnology,
Inc.), anti-Phospho-EGFR (Y1173) (catalog #sc-12351; Santa Cruz Biotechnology),
anti-COX-2 (catalog #160112; Cayman Chemical), anti-E-cadherin (catalog #610182;
BD Biosciences), anti-fibronectin (catalog # 610077; BD Biosciences), anti-vimentin
(catalog #AB-1620; Chemicon International), anti-N-cadherin (catalog #4061S; Cell
Signaling), and anti-β-actin (catalog #A-5441; Sigma-Aldrich).
3.2.4 SIRNA TRANSFECTION
Using Invitrogen Oligofectamine 2000 reagent (catalog # 12252-001), SUM149
cells were transfected with COX-2 or EGFR-targeted siRNA. The COX-2 siRNA
oligonucleotide sequences # 1 (forward 5’GAAUCAUUCACCAGGCAAA-3’ and reverse
5’-UUUGCCUGGUGAAUGAUUC-3’)

and

#2

(forward

5’-

CUCCAAACACAGUGCACUA-3’ and reverse 5’-UAGUGCACUGUGUUUGGAG-3’)
were transfected into SUM-149 cells at 200 nM final concentration per well. Into a 6well plate containing 3 x 105 SUM149 cells/well. At the 4h time point, complete medium
was added at 1 mL/well. At 48h post-transfection, cells were harvested and lysed with
1:10 dilution of 10X RIPA cell lysis buffer (125 mL 1M Tris-HCL PH 7.4, 25 mL NP-40,
12.5 mL SDS, 5 mL 0.5 M EDTA, 12.5 g NaDOC, 75 mL 5M NaCl2 , and 7.5 mL
distilled H2O).
3.2.5 PROSTAGLANDIN EXTRACTION AND ANALYSIS
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Endogenous PGE2 and PGF2α were extracted from IBC and non-IBC cells, and
PG levels were analyzed by using quantitative high-performance liquid chromatography
tandem mass spectrometry (HPLC-MS/MS) according to the protocol of Yang et al. (3).
Briefly, cell pellets were suspended in 0.5 mL of PBS, 40 µL of 1 N citric acid, and 5 µL
of 10% (w/v) butylated hydroxytoluene. PGs were extracted by liquid-liquid extraction
using 2 mL of 1/1 ethyl acetate/hexanes (v/v), three times. The organic layers were
separated, pooled, and evaporated to dryness under nitrogen. The samples were
reconstituted in 100 µL of 50/50 methanol/0.1% acetic acid (v/v). Prostaglandins were
detected using an Agilent 6460 triple quadrupole mass spectrometer (Agilent
Technologies, Palo Alto, CA) equipped with an Agilent HP 1200 binary HPLC pump.
PGE2 and PGF2α were separated using a 2 × 100-mm Kinetex 3 μm C18 analytical
column (Phenomenex, Torrance, CA). Mobile phase A consisted of 0.1% formic acid,
and mobile phase B was acetonitrile with 0.1% formic acid. Compounds were eluted
with a gradient starting at 20% B and ramped to 90% B over 14 minutes. The column
temperature was maintained at 40°C, and samples were kept at 4°C during the
analysis. For the detection and quantification of PGE2 and PGF2α levels in SUM149
xenograft tumors from mice, following tumor extraction the tissue samples were
processed and reconstituted prior to analysis by liquid chromatography tandem mass
spectrometry (LC-MS/MS) as follows in Pirman D.A. et al (55).

3.2.6 QRT2PCR
Total RNA was extracted using the RNeasy Mini kit (Qiagen). Real-time
quantitative RT-PCR was performed using the Bio-Rad iScript One-Step RT-PCR kit.
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7S rRNA was used as a housekeeping gene. The relative quantitation value for each
target gene compared to the calibrator for that target was expressed as 2-(Ct-Cc) (Ct and
Cc are the mean threshold cycle differences after normalization to 7SL rRNA). 7SL
primers were as follows: forward 5’-ATCGGGTGTCCGCACTAAGTT-3’; reverse 5’CAGCACGGGAGTTTTGACCT-3’.
The relative expression levels of samples were presented using a semi log plot. The
sequences of the primers used in this study were as follows: E-cadherin: forward 5’AGTGCCAACTGGACCATTCA-3’, reverse 5’-TCTTTGACCACCGCTCTCCT-3’; Ncadherin:

forward

5’-ACTCGCAGACGCTCACACGC-3’,

GCGGGACTCGCACCAGGAGT-3’;
CCATCACTGTGTATGCTGTC-3’,
Snail:

forward

fibronectin:
reverse

reverse
forward

5’5’-

5’-TGGTTTGTCAATTTCTGTTCGG-3’;

5’-TCCAGGCTCGAAAGGCCTTCAAC-3’,

reverse

5’-

GCAGCGTGTGGCTTCGGATGT-3’; Slug: forward 5’-GGGTGACTTCAGAGGCGCCG3’,

reverse

5’-GGCGGTCCCTACAGCATCGC-3’;

vimentin:

forward

5’-

CAAGGGCCAAGGCAAGTCGCG-3’, reverse 5’-ACGCGGGCTTTGTCGTTGGTTA-3’;
and

Nodal

forward

5’-AGCATGGTTTTGGAGGTGAC-3’,

reverse

5’-

CCTGCGAGAGGTTGGAGTAG-3’.
3.2.7 FLOW CYTOMETRY ANALYSIS
For the detection of CSC markers, SUM149 cells were collected by
trypsinization and stained with anti-CD44 and anti-CD24 antibodies and analyzed by
multicolor flow cytometry. Briefly, combinations of fluorochrome-conjugated monoclonal
antibodies against human CD44 (fluorescein isothiocyanate; catalog #555478; BD
Biosciences) and CD24 (phycoerythrin; catalog #555428; BD Biosciences) or their
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respective isotype controls were added to the cell suspension at concentrations
recommended by the manufacturer and incubated at room temperature in the dark for
30 minutes. The labeled cells were washed and resuspended in FACS buffer (PBS +
1% FBS) and then analyzed on a FACSVantage flow cytometry system (BD
Biosciences). Cell populations with high aldehyde dehydrogenase (ALDH) enzymatic
activity were identified using an ALDEFLUOR fluorescent reagent system according to
the manufacturer’s method (STEMCELL Technologies Inc., Vancouver, Canada).
Briefly, 1 × 106 SUM149 cells were collected following trypsinization, and 2.5 × 105 cells
were resuspended in Aldefluor assay buffer containing ALDH substrate. As a negative
control, we used di-ethylaminobenzaldehyde, a potent inhibitor of ALDH activity. Cells
were then incubated at 37°C for 30 minutes with Aldefluor, washed with Aldefluor assay
buffer, and stained with 1 µg/mL propidium iodide (Sigma) to discriminate viable cells
from dead cells before detection in the green fluorescence channel (520-540 nm) on
the flow cytometer (Beckman Coulter Gallios Instrument).

3.2.8 CELL MIGRATION AND INVASION ASSAYS
MDA-MB-231 scrambled shRNA and RANK shRNA cells were serum starved for
24 hours prior to stimulation with 25 ng/mL human soluble RANKL (product #R138;
Leinco Technologies, Inc. St. Louis, MO) for 24 hours. For Boyden chamber trans-well
migration assay (n=3), 1.5 × 105 cells in serum-free medium were layered in the top
chamber of 24-well trans-well plates with serum-free media containing RANKL (25
ng/mL) in the lower chamber and incubated at 37°C for 6 hours. Cells in the top
chamber (non-migrated) were removed, and cells in the bottom chamber (migrated)
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were fixed with 0.1% crystal violet/20% methanol solution. For the invasion assay
(n=3), 1.5 × 105 cells were plated in serum-free medium in the upper chamber of a
Boyden chamber coated with BD Basement Membrane Matrigel Growth Factor
Reduced Phenol Red Free with serum-free media containing RANKL (25 ng/mL) in the
lower chamber. Twenty-four hours later, non-invading cells were removed from the
upper chamber, and the underside membranes were fixed and stained as above in the
cell migration assay. Migrated and invaded cells were quantitated by dissolving stained
cells in a solution of 4% sodium deoxycholate and performing colorimetric reading of
optical density at 595 nm. Results were analyzed using unpaired Student’s t-test with a
*P value < 0.05 considered significant.
3.2.9 MAMMOSPHERE ASSAY
SUM149 or KPL-4 cells were plated into a 6-well plate at a density of 3 × 105
cells/well and pretreated for 24 hours with 10, 25, or 50 µM celecoxib. As a control,
cells were pretreated with DMSO. For generation of primary mammospheres, SUM149
cells were seeded at 2 × 104 cells/well or KPL-4 cells were seeded at 2.5 × 103
cells/well into an ultra-low-attachment 6-well plate containing Mammocult Basal
Medium (catalog #05621; STEMCELL Technologies, Inc.) supplemented with 1%
Proliferation Supplement (catalog# 05621; STEMCELL Technologies, Inc.), 2 µg/mL
Heparin (catalog #07980; STEMCELL Technologies, Inc.), and 0.12 µg/mL
hydrocortisone (catalog #07904; STEMCELL Technologies, Inc.) with celecoxib or
DMSO.

On

day

5,

primary

mammospheres

were

passaged

to

secondary

mammospheres. Both primary and secondary mammosphere conditions were tested in
triplicate. Mammospheres were quantitated on day 5 by staining with MTT reagent (0.4
mg/mL) for 2 hours and enumerated using GelCount software (Oxford Optronix).
68

Results were analyzed using unpaired Student’s t-test with a P value < 0.05 being
considered significant.
3.2.10 THREE-DIMENSIONAL (3D) MATRIGEL ASSAY
As a surrogate model for the invasive-like epithelial-to-mesenchymal (EMT)
phenotype, the three-dimensional (3D) Matrigel assay was created to allow for the
assessment of the ‘invasiveness’ of cells in a basement layer-like substrate. During the
migratory process of breast cancer cells, the cells must invade the surrounding stroma
which encapsulates the luminal and basal layers of the mammary tissue. The cells
ability to transverse the basal layer is represented in the cells’ ability to invade the
basement membrane and help organize communication between cells embedded
within the matrix as in the 3D-Matrigel assay. Matrigel is an enriched substance
composed of key growth factors found in the basement membrane of tissue including
factors found in the extracellular membrane (ECM) (106). The Matrigel used was
derived from Engelbreth-Holm-Swarm (EHS) mouse sarcoma and contained the
components laminin, collagen IV, heparin sulfate proteoglycans, and entactin/nidogen.
Corning Basement Membrane Matrix (catalog #356234; BD Biosciences) was thawed
on ice, and a bottom layer consisting of 65 µL of Matrigel solution was added per well
into a four-well chamber slide (Lab-Tek II; Nalge Nunc International, Rochester, NY)
then incubated at 37°C for 30 minutes to allow for solidification. Then 5 × 104 cells were
resuspended in 500 µL of culture medium supplemented with 2% Matrigel on ice and
added to the solidified bottom layer. At 24-hours post-incubation at 37C, images of the
cell projections were captured and tube formation (invasive structures) was quantitated
using S.CORE (S.CO LifeSciences GmbH, Munich, Germany) or Wimasis (GmbH,
Munich, Germany) analysis software.
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3.2.11 IBC XENOGRAFT MODEL
All animal experiments were approved by the Institutional Animal Care and Use
Committee (IACUC protocol 02-03-02134) of MD Anderson Cancer Center. A total
volume of 0.15 mL of SUM149 cell suspension containing 2 × 106 cells with 50%
Matrigel was injected into the fourth inguinal mammary gland of 8-week old female
nu/nu mice. The mice were fed ad libitum with a regular diet for 3 weeks, at which time
the tumors were well established. The mice were then randomly allocated (n=8 per
group) to control diet (regular food pellets) or to one of two treatment diets, 250 ppm or
500 ppm celecoxib, for the following 5 weeks. Mice were weighed and estimated to be
about 25 g/mouse and food intake per mouse was estimated to be about 3 g/day. The
diet dose was calculated based on the formula: diet dose (DD) = Single daily dose (SD)
x body weight (BW) x daily food intake (FI) (www.researchdiets.com/resourcecenter/diet-dose-calculator.com; Research Diets, Inc. New Brunswick, NJ). The 250
and 500 ppm (mg/kg of mouse body weight/day) diet dose translated to approximately
2083 mg of celecoxib/kg BW, and approximately 4167 mg of celecoxib/kg BW,
respectively. Tumor volumes were determined by calculating weekly caliper
measurements using the following formula: tumor volume (V) = (L × W2) × 0.5, where L
is the length and W is the width of the tumor. Tumor growth inhibition (%) was
calculated as 1 - (tumor volume change of treatment group / tumor volume change of
control group) × 100%.
3.2.12 STATISTICAL ANALYSIS
Data are presented as mean ± SD except where otherwise stated. When two groups
were compared, Student’s t-test was used (P < 0.05 was considered significant).
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3.3 RESULTS
3.3.1 IN VITRO TARGETING OF COX-2 AND EGFR IN IBC CELLS
We proposed EGFR to regulate the expression of COX-2 in IBC cells since we
initially found a positive correlation between EGFR and COX-2 expression levels in IBC
tumor samples (Figure 3.1). In determining if this correlation existed in IBC cell lines at
the protein level, we immunoblotted for COX-2, and activated EGFR in IBC and nonIBC cell lines. We observed the IBC cell line SUM149 to co-express both COX-2 and
activated EGFR (Figure 3.2). We observed EGF stimulation to increase COX-2 protein
expression in SUM149 cells (Figure 3.3), and EGFR-targeted siRNA to suppress COX2 expression (Figure 3.4). In addition, we observed erlotinib treatment in SUM149 cells
to decrease COX-2 expression (Figure 3.5). The occurrence of decreased COX-2
levels subsequent to suppressed EGFR expression and activity indicated that EGFR
positively regulates COX-2 expression in SUM149 cells. This finding supports our
hypothesis that EGFR positively regulates COX-2 in IBC cells. As previous findings
suggested that COX-2-activated expression is regulated through the EGFR pathway
(34), we investigated the levels of PGs to assess COX activity following treatment with
celecoxib and erlotinib and vehicle-treated SUM149 cells at 24h and 48h time points
(Figure 3.6). Basal levels of PGs (PGE2 and PGF2α) were checked in a panel of IBC
and non-IBC cell lines (Figure 3.7), in which we found PGs to be higher in the IBC cell
lines compared to the non-IBC cell lines. Collectively, these findings suggest EGFR to
regulate the expression and activity of COX-2 in IBC cells and that pharmacological
intervention with COX-2 or EGFR-targeted therapy may reduce the tumorigenicity of
IBC cells as observed by the downregulation of PGE2, the most tumorigenic byproduct
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of COX-2 activity. In determining whether COX-2 plays a functional role in the
tumorigenicity and progression of IBC cells, we investigated the biological function of
COX-2 in in vitro studies and an in vivo study.
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Figure 3.1 EGFR correlates with COX-2 gene expression in breast cancer. We
correlated EGFR and COX-2 gene expression in IBC (n=25) and non-IBC (n=57) tumor
samples constructed on an Affymetrix cDNA microarray. The correlative analysis was
performed using the Spearman’s Rank Correlation Coefficient analysis. IBC data (Pvalue = 0.01; rho = 0.51); non-IBC data (P-value = 0.04; rho = 0.269).
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Figure 3.2 COX-2 and EGFR expression in IBC and non-IBC cell lines.
SDS-PAGE was performed using total protein lysate samples collected from IBC and
non-IBC cell lines cultured under normal conditions. A western blot was performed to
immunoblot for basal level expression of COX-2, EGFR, and p-EGFR in IBC and nonIBC cell lines. Β-actin was used as a loading control.
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Figure 3.3 EGF stimulates COX-2 expression in SUM149 cells.
SUM149 cells were serum-starved then stimulated with 0.1 µg/mL of EGF in serumfree medium for the time points as indicated (15, 30, or 60 minutes and 4 or 24 hours).
Ctl; untreated control. COX-2, EGFR, and p-EGFR proteins were immunoblotted. Βactin was used as a loading control. Odyssey imager was used to detect the protein.
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Figure 3.4 Suppression of EGFR expression reduced COX-2 expression in
SUM149 cells. SUM149 cells were transiently transfected with pooled EGFR-targeted
siRNAs, negative siRNA, or not transfected as a control for 48 hours prior to harvesting
and lysing cells to collect and isolate total protein lysate. A total of 30 µg of protein was
loaded/well for SDS-PAGE on a 8% resolving gel and transferred to a PVDF
membrane. The membrane was immunoblotted with primary antibodies for pEGFR,
total EGFR, and COX-2. β-actin was immunoblotted as a loading control. Samples
were probed with AlexaFluor (680 nm) secondary antibody. The membrane was
scanned using the LI-COR imager. NT; non-transfected, neg; negative, and si; siRNA.
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Figure 3.5 Erlotinib reduced COX-2 levels in SUM149 cells.
SUM149 cells were treated with EGFR-specific tyrosine kinase inhibitor, erlotinib, for 48
and 72 hours prior to immunoblotting for COX-2 and β-actin as a loading control. Ctl;
untreated control.
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Figure 3.6 Celecoxib and erlotinib reduced PGE2 and PGF2α levels in SUM149
cells. SUM149 cells were treated with celecoxib (10 µM), erlotinib (0.5 µM), or DMSO
(control) for 48 hours prior to collecting cells and cell media for analysis. Each sample
contained 3 x 106 cells/mL of 1X PBS for HPLC/MS analysis of insoluble PGE2
(measured from cells collected at 48 hours post-treatment) and soluble PGF2α
(measured from media collected at 48 hours post-treatment). Quantitated PGE2 and
PGF2α levels were calculated as ng/mL/106 cells and results were graphed using
GraphPad Prism version 6.01 software.
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Figure 3.7 IBC cell lines have higher levels of COX activity compared to non-IBC
cell lines. Under normal culture conditions, a panel of human IBC and non-IBC cell
lines were analyzed for soluble PGE2 and PGF2α levels at 1 x 106 cells/mL of 1X PBS by
HPLC/MS analysis. Quantitated soluble PGE2 concentrations (ng/mL/106 cells) and
PGF2α (% relative to SUM149) were graphed using GraphPad Prism version
6.01software.
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3.3.2 COX-2 REGULATES IBC CELL MIGRATION AND INVASION
Previous studies have found COX-2 to regulate the tumorigenicity and
invasiveness of breast cancer cells, however, the mechanism by which COX-2
promotes IBC tumorigenicity and invasiveness has not been well studied in IBC (58,
64). PGE2 is known to have tumorigenic effects, and to promote a stem cell-like
phenotype, however, this link remains to be elucidated in IBC. In finding out whether
the COX-2 pathway is required for IBC cell migration and invasion, we performed a cell
migration and invasion assay using SUM149 cells. Cells were serum-starved for 24
hours prior to stimulation with 0.5 µM PGE2 or PGF2α or untreated as a control for 24
hours. We observed SUM149 cell migration and invasion significantly increased by
PGs (Figure 3.8), while celecoxib decreased SUM149 cell migration and invasion
(Figure 3.9).
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Figure 3.8 Prostaglandin stimulation increased SUM149 cell migration and
invasion. SUM149 cells were serum-starved for 24 hours then either left untreated as
a control or treated with PGE2 or PGF2α (0.5 µM) in triplicate for 24 hours. Cells were
seeded at 2.5 x 105 cells/well in which cells were incubated with serum-free media
containing PG or without PG (untreated) for A) 6-hour cell migration assay (n=3) or B)
24-hour cell invasion assay (n=3). Migrated and invaded cells were stained with 0.1%
crystal violet/20% methanol solution for 5 minutes and under a light microscope cells
were counted and averaged per well. Results were graphed using GraphPad Prism
version 6.01 software. *P= 0.002; **P < 0.0001.
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Figure 3.9 Celecoxib inhibited the migration and invasion of SUM149 cells.
SUM149 cells were pre-treated with 50 µM of celecoxib or untreated in triplicate for 24
hours prior to seeding at a density of 2.5 x 105 cells/well for A) 6-hour cell migration
assay (n=3), or B) 24-hour cell invasion assay (n=3). Migrated and invaded cells were
stained with 0.1% crystal violet/20% methanol solution for 5 minutes then dissociated
from the membrane by incubation with 4% sodium deoxycholate for 20 minutes.
Samples were quantitated by luminescence (595 nm) using Perkin-Elmer Victor X
microlabel plate reader. Results were graphed using GraphPad Prism version 6.01
software. *P < 0.01.
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3.3.3 THE EMT AND CANCER STEM -LIKE CELL PHENOTYPE IN IBC CELLS IS REGULATED
BY THE COX-2 PATHWAY
The reversible process of EMT allows cells to acquire molecular features such
as upregulation of mesenchymal markers Fibronectin, Vimentin, N-cadherin, and
transcription factor Twist, and downregulation of epithelial marker E-cadherin. Whether
through PG stimulation or treatment with a selective COX-2 inhibitor, the COX-2
pathway is shown to play a role in EMT in breast cancer cells. The link between the
COX-2 pathway, EMT and stem-like properties has not been elucidated in IBC cells. To
investigate whether the COX-2 pathway regulates EMT and stem-like properties in IBC
cells, we treated SUM149 cells with PGs (0.5 µM) or celecoxib (10 or 25 µM) and
immunoblotted for EMT markers. We observed PGs to down-regulate E-cadherin, while
up-regulate mesenchymal markers, Fibronectin, Vimentin, and Twist (Figure 3.10 left
panel). In celecoxib-treated SUM149 cells, E-cadherin was up-regulated, while
mesenchymal markers, Fibronectin, Vimentin, and N-cadherin were down-regulated
(Figure 3.10 right panel). In addition, we observed celecoxib-treated SUM149 and KPL4 IBC cells to demonstrate a reduction in projection formation in 3D matrigel culture
(Figure

3.11).

PG-stimulation

increased

the

CSC

population,

CD44+/CD24-

subpopulation, in SUM149 cells (Figure 3.12). Aldefluor (ALDH1) activity in SUM149
cells were increased by PGs, but decreased by celecoxib (Figure 3.13). The formation
of SUM149 primary and secondary mammospheres
(Figure 3.14).
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was decreased by celecoxib

Figure 3.10 The expression of EMT markers are regulated by COX-2 activity in
SUM149 cells. SUM149 cells were stimulated with PGE2 or PGF2α (0.5 µM) or
unstimulated as a control (Ctl) for 72 hours under serum-free conditions following a 24
hour starvation and lysate was immunoblotted for EMT markers (left panel). SUM149
cells were treated with vehicle control (0), or celecoxib (10 or 25 µM) for 48 hours and
cell lysate was immunoblotted for EMT markers (right panel). Β-actin was
immunoblotted as a loading control.
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Figure 3.11 Celecoxib suppressed the EMT-like phenotype in 3D Matrigel culture.
SUM149 cells and KPL-4 cells were treated with celecoxib (2, 10, and 50 µM) or
untreated (0) in triplicate for 24 hours in 2D culture and under Matrigel culture
conditions for another 24 hours. Images of the projections or tube formations (not
shown) were taken using a light microscope connected to a Nixon camera. Projections
were quantitated and averaged by S.Core for SUM149 EMT assay and Wimasis for
KPL-4 EMT assay. Using GraphPad Prism version 6.01 software, results were
calculated as a percentage of projections formed relative to untreated cells.
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Figure 3.12 Prostaglandins increased the CD44+CD24- cell population in SUM149
cells. SUM149 cells were stimulated with PGE2 or PGF2α (0.5 µM) for 24 hours prior to
staining with FITC-CD44 and PE-CD24 antibodies. Untreated control SUM149 cells
had a 49.5% CD44+CD24- subpopulation, while PGE2 and PGF2α stimulated SUM149
cells had a CD44+CD24- subpopulation of 66.7% and 66.5%, respectively.
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Figure 3.13 COX-2 increased the Aldefluor activity of SUM149 cells. SUM149 cells
were stimulated with PGE2 or PGF2α for 6 days and the aldefluor activity was detected
by flow cytometry after treatment. *P = 0.0109; **P = 0.0016 (left panel), or treated with
celecoxib for 4 days and detected for Aldefluor activity by flow cytometry, *P = 0.0013;
**P = 0.0003 (right panel).

87

Figure 3.14 Celecoxib reduced SUM149 mammosphere formation. SUM149 cells
were plated at a density of 3 x 104 cells/well and treated with DMSO as a control (n=3)
or celecoxib (10 µM) (n=3) for 5 days under mammosphere conditions in a lowattachment plate. Live cells dissociated from primary (P0) mammospheres were stained
with trypan blue solution and counted using the Cellometer prior to re-plating and
culturing for secondary (P1) mammospheres.

Mammospheres were stained with 5

mg/mL MTT reagent and enumerated after 5 days using GelCount plate reader and
software. *P < 0.005.
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3.3.4 THE TUMORIGENICITY OF IBC IS SUPPRESSED BY CELECOXIB
The aggressiveness of IBC is likely due to the stem cell-like phenotype which
promotes tumorigenicity (64). As observed with other breast cancer subtypes, COX-2
activity has tumorigenic effects, which can be inhibited by the selective COX-2 inhibitor
celecoxib. In a previous study, we had observed erlotinib, an EGFR inhibitor, to
suppress IBC tumorigenicity and metastasis (34). To determine whether celecoxib has
anti-tumorigenic effects in an IBC xenograft mouse model, we treated an orthotopic
SUM149 xenograft mouse model with celecoxib. We investigated the effects of
celecoxib on IBC tumorigenicity by the measurement of tumor growth and the levels of
PGE2 and PGF2α in the tumors. We observed celecoxib treatment to significantly reduce
tumor growth compared to control (untreated) mice (Figure 3.15). In addition, we found
PG levels to be lower in tumors derived from celecoxib-treated mice compared to
control mice (Figure 3.16). Since EMT is a stem cell-like characteristic associated with
the invasiveness and CSC population in breast cancer, we analyzed the expression of
epithelial and mesenchymal markers including Nodal, an embryonic stem cell regulator
found to be highly expressed in invasive breast cancers. Relative to the control tumors,
we found epithelial marker, E-cadherin, up-regulated in celeocoxib-treated tumors,
while mesenchymal markers, Fibronectin, N-cadherin, Snail, Slug, Vimentin, and stem
cell regulator, Nodal, down-regulated in celecoxib-treated tumors (Figure 3.17).
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Figure 3.15 Celecoxib reduced SUM149 tumor growth in mice. A solution of 50%
Matrigel/ 2 x 106 SUM149 parental cells were orthotopically injected into the fifth
inguinal mammary fat pad of 8 week old female nu/nu mice (n=24) and treated with 250
ppm (n=8) or 500 ppm (n=8) celecoxib diet or control (normal) diet (n=8) following initial
tumor formation by week 3. Tumor volumes were measured twice/week using calipers
over a period of five weeks. The inhibition of tumor growth rate was calculated and
results were graphed using GraphPad Prism version 6.01 software. P-value was
determined by student t-test; *P = 0.0215, **P = 0.0011.
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Figure 3.16 Celecoxib reduced the levels of PGE2 and PGF2α in orthotopic tumors
in mice. Resected tumors from the mice were homogenized and cells were
resuspended and lysed prior to analysis by LC-MS/MS for PGE2 and PGF2α levels (ng)
relative to total protein (mg) determined by Bradford Assay.
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Figure 3.17 EMT markers were modulated by celecoxib treatment in SUM149
xenograft

tumors.

Epithelial marker E-cadherin and mesenchymal markers

(Fibronectin, N-cadherin, Snail, Slug, and Vimentin) including stem cell marker, Nodal,
were measured in SUM149 xenograft tumors by qRT PCR. Celecoxib-treated (250 ppm
and 500 ppm) mice had increased E-cadherin and reduced mesenchymal markers
relative to control treated mice. Expression of stem cell regulator, Nodal, was reduced
in tumors from celecoxib-treated mice.
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3.3.5 RECOMBINANT HUMAN NODAL MITIGATES THE EFFECTS OF CELECOXIB IN IBC CELLS
Following our observation that celecoxib treated mice with xenograft SUM149
tumors downregulated Nodal gene expression, we predicted that the inhibition of COX2 in IBC cells has anti-tumorigenic effects by suppressing the Nodal pathway. To
further investigate COX-2 regulation of Nodal, we investigated the in vitro effects of
celecoxib on Nodal expression in SUM149 cells by analyzing Nodal gene expression in
cells cultured in vitro in 3D Matrigel. We observed PGE2 and PGF2α stimulation to
increase Nodal expression while celecoxib decreased Nodal expression in SUM149
cells (Figure 3.18). To determine the potential anti-metastatic effects of celecoxib in
IBC and regulation of the CSC phenotype, we tested the combination treatment of
celecoxib with recombinant human Nodal (rhNodal) on the migration, invasion, and
mammosphere formation of SUM149 cells. We observed celecoxib to reduce SUM149
cell migration and invasion (Figure 3.19), and mammosphere formation (Figure 3.20)
and rhNodal to mitigate celecoxib-mediated inhibition of SUM149 cell migration,
invasion, and mammosphere formation.
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Figure 3.18 COX-2 regulates Nodal expression in SUM149 cells in 3D Matrigel
culture. SUM149 cells were treated with 0.5 µM PGE2 or PGF2α for 48 hours (right
panel) or treated with celecoxib for 24 hours under 3D Matrigel culture conditions (left
panel) prior to qRT PCR analysis for Nodal expression levels (n=3). Fold-change in
Nodal expression was measured relative to control (untreated) SUM149 cells in 3D
Matrigel culture.
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Figure 3.19 Recombinant human Nodal mitigated celecoxib-mediated inhibition
of SUM149 cell migration and invasion. SUM149 cells were pre-treated with
celecoxib (25 µM) or rhNodal (100 ng/mL), or in combination prior to a 6 hour cell
migration and 24 hour cell invasion assay (n=3). Cells were stained with 0.1% crystal
violet/20% methanol solution for 5 minutes then dissolved using 4% sodium
deoxycholate. Migrated or invaded cells were quantified by luminescence imaging
using a Perkin-Elmer multilabel plate reader (595 nm).
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Figure 3.20 Recombinant human Nodal mitigated the effects of celecoxib in
SUM149 mammosphere formation. SUM149 cells were treated with celecoxib or
rhNodal alone, or in combination under mammosphere assay conditions. Primary
mammospheres were passaged following cell counting to re-plate 3 x 104 cells/well for
secondary mammosphere formation prior to staining with 5 mg/mL MTT reagent and
quantification by GelCount software.
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3.4 DISCUSSION
To determine if there was a correlation between EGFR and COX-2 in IBC, we
performed a cDNA microarray analysis using IBC and non-IBC patient cohorts. Based
upon the observation of a significantly tighter correlation between EGFR and COX-2
gene expression in IBC primary compared to non-IBC tumors, and IBC cell lines with
higher levels of PGE2 and PGF2α, it is conceivable that EGFR-positive IBC cells may
elicit an increased sensitivity to COX-2 inhibition. Our observation of EGFR and COX-2
correlation in IBC and non-IBC is in accordance with other reported links between
COX-2 and HER family members, such as EGFR and HER2/neu. In a study reported
by Subbaramaiah et al. the overexpression of HER2 was associated with increased
levels of COX-2 in human breast cancers, and COX-2 is the functional intermediate
linking HER2 and aromatase, suggesting that inhibitors of PGE2 synthesis may
suppress estrogen biosynthesis in breast tissue (107, 108). The significance of COX-2
in IBC has not been thoroughly investigated and the biological role of COX-2 in EGFRexpressing IBC is unknown. Our study is the first one to find a correlation between
EGFR and COX-2 gene expression in an IBC cohort, which suggests the importance of
COX-2 in EGFR regulation in IBC. IBC is a heterogeneous breast cancer subtype,
which has not been molecularly differentiated from non-IBC. By gene expression
profiling, it was reported that IBC is composed of several TNBC molecular subtypes
described in non-IBC tumors by Lehmann B.D. et al.; however, IBC was not found to be
specific for either one of the molecular subtypes (9, 17). The pathological complete
response (pCR) rate was observed to be lower in TN-IBC compared to HR+ and
HER2+ IBC patients suggesting poorer prognosis in TN-IBC patients (109). By
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stratifying IBC tumors by TNBC molecular subtypes, we may be able to identify EGFR
and COX-2 expressing IBC tumors with a specific TNBC molecular subtype.
Upon observing a correlation between COX-2 and EGFR expression in IBC
tumors along with elevated PGE2 and PGF2α levels in a panel of IBC cell lines
compared to non-IBC cell lines, we investigated EGFR-regulation of COX-2 expression
and activity via EGFR-targeted siRNA or erlotinib treatment with erlotinib. Based on our
findings, we concluded that the EGFR pathway regulates COX-2 expression and
activity in IBC cells. It was reported that the regulation of COX-2 expression in breast
cancer cells may occur through activation of the PI3K/AKT and MAPK pathways by
EGFR (110). The regulation of COX-2 could potentially occur through the MAPK
pathway,

which

transcriptionally
activates
expression

of

COX-2

in

addition

to

several

other

proteins involved
in breast tumor
invasion

and

migration.

Our

ILLUSTRATION 3.4 A PROPOSED MODEL FOR EGFR/COX-2MEDIATED NODAL SIGNALING IN IBC CELLS

Cross-talk signaling between EGFR and COX-2 may activate ERK1/2
signaling and stimulate transcription of the NODAL gene through
hypothesized
phosphorylation of SMAD2 linker region and maintaining a positive
model implicates feedback loop enhancing Nodal signaling in the cell. Deregulation of
the Nodal pathway leads to enhanced cell motility and invasion.
the extracellular
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signal-regulated kinase 1/2 (ERK1/2) pathway downstream of EGFR (illustration 3.4).
Our rationale for speculating that the ERK1/2 pathway may be the key mediator
for EGFR/COX-2 activity is also based on a prior investigation in our laboratory in
which inhibition of ERK1/2 but not PI3K/AKT resulted in a synergistic outcome in
combination with erlotinib treatment of IBC cells (34). Determining whether
EGFR/COX-2 regulates Nodal in an ERK/1/2 dependent manner remains to be
determined in future studies.
We observed that in in vitro studies the COX-2 pathway promoted IBC cell
migration and invasion, and the invasive-like EMT phenotype. In an in vivo SUM149
xenograft mouse model, the inhibition of tumor growth by celecoxib occurred
concomitantly with the down-regulation of EMT-associated events, including decreased
Nodal expression. Our study demonstrated that the COX-2 pathway regulated the CSC
population in SUM149 cells as suggested by our results from surrogate cancer stem
cell assays, mammosphere formation assay, Aldefluor assay, and CD44+/CD24-/low
staining and flow cytometry analysis. Based on our findings, we concluded the
suppression of COX-2 to block the progression and metastatic potential of IBC cells
through down-regulation of the CSC population. Recent studies have linked the
progression of breast cancer to CSCs and that targeting CSCs might be an effective
strategy to circumvent drug resistance and reduce tumor recurrence (111). IBC is
considered to be a highly aggressive breast cancer subtype with a CSC phenotype
(112), and a poor long-term outcome associated with a high risk of relapse. In addition,
prior studies have demonstrated a functional role for COX-2 in EMT and breast cancer
stem cells. It was reported by Bocca C. et al. that hypoxia induced HIF1α expression
which in turn elevated COX-2 expression and promoted an EMT phenotype in breast
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cancer cells (60). Relevant to this study, EMT in IBC cells can potentially be triggered
by elevated COX-2 expression under hypoxic conditions in the presence of growth
factors and cytokines in the microenvironment.
We sought to elucidate the mechanism of COX-2-mediated EMT in celecoxib
treated SUM149 cells. By performing data analysis of celecoxib-modulated gene
expression using a human EMT RT PCR array kit, we observed down-regulation of
embryonic stem cell regulator Nodal in SUM149 cells treated with celecoxib for 72
hours. This result indicated Nodal to be a potential downstream mediator of COX-2mediated IBC cell progression (data not shown). We confirmed Nodal regulation by
COX-2 through in vitro studies and in a SUM149 xenograft mouse model. There is
evidence that Nodal is highly expressed in aggressive breast cancers, such as poorly
differentiated breast cancers (113). The potential role of Nodal in the progression of
IBC was further validated by our observation that recombinant Nodal promoted the
migration and invasion of IBC cells and the CSC phenotype. These results suggest the
therapeutic importance of targeting the COX-2 pathway in patients with IBC. However,
it is not clear if Nodal is a mediator of EGFR-induced COX-2 signaling or is a target of
COX-2 signaling pathway. We speculate that EGFR regulation of COX-2 in IBC cells
promotes the CSC phenotype while Nodal signaling, via SMAD or a non-canonical
pathway, provides positive feedback to COX-2. There is the possibility that
EGFR/COX-2 regulation of Nodal occurs through MAPK ERK1/2 signaling since
ERK1/2 is activated downstream of EGFR and has been shown to phosphorylate
SMAD2 to regulate its nuclear translocation and transcriptional activity (113). A study
showed that inhibition of ERK1/2 pathway mitigated the activity of the Nodal pathway in
breast cancer cells. A more in-depth look at the mechanism of EGFR/ COX-2/Nodal in
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IBC progression will be addressed in future studies to help enhance our understanding
of how EGFR/COX-2 axis regulates the CSC phenotype in IBC. Overall, our results
suggest an important role for COX-2 in promoting EMT and the CSC phenotype in IBC.
As such, targeting of the COX-2 inflammatory pathway may represent an effective
therapeutic approach for inhibiting the progression of IBC.
In summary, we conclude that there is a functional relationship between EGFR
and COX-2, while a correlative relationship exists between COX-2 and Nodal in IBC
cells. Further studies are required to determine if COX-2-mediated regulation of Nodal
is only correlative or if it is causative. This finding could lend to the concept of Nodal as
a pivotal target or biomarker for COX-2-induced CSC phenotype in IBC cells.
SB431542, an inhibitor of the canonical Nodal receptors ALK4 and ALK 7, could be
utilized to block the Nodal pathway and determine whether canonical signaling provides
a positive feedback to promote COX-2 activity and subsequent release production of
inflammatory mediators.
From a clinical perspective targeting COX-2 is efficacious, however there is a
dilemma of potentially harmful side-effects (e.g. cardiotoxicity and gastrointestinal
effects) resulting in the long-term use of selective COX-2 inhibitors. Alternatively, the
EGFR pathway can be inhibited with an EGFR-specific monoclonal antibody,
panitumumab. In an ongoing clinical study of panitumumab in IBC patients, biomarkers
(e.g. COX-2, EGFR, and Nodal) will be assessed and pathological complete response
will also be evaluated at the completion of the study. The use of panitumumab could
reduce EGFR-mediated COX-2 activity without the harmful side-effects associated with
a selective COX-2 inhibitor, leading to an improved response and clinical outcome for
IBC patients.
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CHAPTER 4: THE FUTURE OF TARGETED THERAPY IN
AGGRESSIVE BREAST CANCERS: IBC AND TNBC
From our translational studies, we conclude that the tumorigenicity and
invasiveness driven by the CSC population in IBC and TNBC can be modulated by
COX-2 and RANK signaling. By eradicating the CSC population through inhibition of
one of these two pathways, we can potentially block the progression of IBC and TNBC
helping to reduce metastasis and prolong survival in IBC and TNBC patients.

This is the first study in which RANKL was found to be an independent
prognostic factor in RANK positive TNBC patients. The basis of RANK-mediated TNBC
progression may rely on its interaction with RANKL. Unlike RANK, RANKL is expressed
at relatively low levels in breast tumor cells, while it is highly expressed in breast tumor
stroma (114). In TNBC MDA-MB-231 cells, we found the CSC phenotype to be
regulated by RANK. Our RT2 PCR array analysis revealed stem cell genes modulated
by the suppression of RANK in MDA-MB-231 cells, which provides us insight into which
inflammatory pathways might be involved in the RANK-mediated CSC phenotype in
TNBC. Interestingly, BMP2 and BMP3 were observed to be among the top five stem
cell genes downregulated by the suppression of RANK. BMPs are members of the
TGFβ superfamily, which function to regulate CSCs. The downregulation of BMP2 and
BMP3 gene expression in MDA-MB-231 RANK shRNA cells suggests that RANK is a
potential target for reducing the invasion and progression of TNBC cells. BMPs
modulate the breast cancer cellular cytoskeleton and adhesive structures at the cell
surface to mobilize the cell during migration and invasion (115). The role of BMPs in
cancer stem cells is not clear, however, it has been documented that BMPs can
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promote a CSC phenotype, including EMT, through stimulation of the SMAD1/5/8
pathway. An in vivo TNBC spontaneous metastasis mouse model will allow us to
investigate the effects of RANK suppression on the invasion and metastasis of TNBC
cells, and detect stem cell markers modulated downstream of RANKL/RANK in primary
and metastatic tumors.
Preventing the metastasis of TNBC is of high clinical priority for patients and by
targeting the RANKL/RANK pathway we can potentially block the progression of TNBC.
From our analysis of RANK and RANKL expression in clinical specimens of TNBC, we
observed that RANK expression is not a poor prognostic indicator and therefore, we
need to evaluate RANK and RANKL in a prospective clinical trial. An ongoing phase II
clinical trial (NCT01952054) at MD Anderson Cancer Center has been initiated to study
the effects of the RANKL inhibitor, denosumab, on bone metastasis in breast cancer
patients by monitoring for circulating tumor cells (CTCs) and disseminated tumor cells
(DTCs) and identifying bone metastasis-relevant biomarkers including RANK and
RANKL. In this particular clinical trial, the patient cohort will be estrogen receptor (ER)positive advanced breast cancer patients. ER-dependent breast tumors have a
tendency to develop bone metastases at a two-fold higher rate compared to non-ER
breast tumors (116). Although this particular clinical trial is not targeted at TNBC
patients, findings from this study may elude to whether the co-expression of RANK and
RANKL in breast tumors is a predictive indicator for poorer outcome and if denosumabtreated patients have improved skeletal-disease free survival and reduced bone
metastases. To evaluate RANK and RANKL expression and the efficacy of denosumab
in a TNBC subtype-specific (BL1, BL2, M, MSL, LAR, and IM) cohort, patients would be
randomly assigned to receive either denosumab or placebo (control) treatment. By
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stratifying TNBC patients, based on the six gene expression profiles described by
Lehmann BD et al.(12), we can determine if there is an association between TNBC
subtype and favorable response to denosumab therapy. Findings from this clinical
study will provide insight into whether targeting the RANKL/RANK pathway in TNBC is
clinically relevant and if blocking the RANKL/RANK pathway will result in reduced
metastasis and improved clinical outcome.
In IBC, we observed a positive regulation of COX-2 by EGFR in IBC, and made
a novel finding that the COX-2 pathway regulates the expression of Nodal and the CSC
phenotype of IBC cells. To this end, we conclude that inhibition of the Nodal pathway
could be an effective strategy to eradicate CSCs in COX-2 expressing tumors.
However, the mechanism of Nodal regulation by COX-2 is yet to be validated and
whether targeting the Nodal pathway will suppress IBC tumorigenicity and metastasis
remains unknown. We will further investigate the requirement for COX-2 and Nodal in
tumor progression by assessing the efficacy of a combined celecoxib and SB431542
(an inhibitor of canonical Nodal signaling) therapy in IBC cells. EGFR, COX-2, and
Nodal are linked with inflammation in breast cancer as they each are upstream
regulators of transcription activators that promote the gene expression of several
inflammatory molecules involved in breast cancer progression. To study the role of
inflammation in IBC, a future clinical trial for the treatment of IBC patients will
investigate the effects of targeting the COX-2 pathway via EP4 receptor inhibitor, and
identify novel inflammatory markers modulated by the inhibition of the EP4 receptor.
This study will allow us to investigate a novel therapeutic approach to targeting COX-2mediated inflammatory response in IBC.
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Potentially, the RANK and COX-2 pathways can converge to induce an
inflammatory response in IBC and TNBC. We found several stem cell genes modulated
by the suppression of RANK in the TNBC cells that are linked with inflammatory
signaling pathways activated in breast cancer cells. The RANKL/RANK can activate
NFkB transcriptional activity, leading to the induction of COX-2 gene expression. In turn,
activation of the COX-2 pathway can stimulate the production and secretion of PGE2,
leading to an upregulation of RANKL and RANK gene expression (117). In addition to
NF-kB, the AP-1 transcription factor, which activates the expression of the COX-2 gene,
PTGS2, can be upregulated by the JNK pathway downstream of RANKL/RANK (117).
While it is not clear which downstream pathway is involved in the regulation of
RANKL/RANK activity of TNBC cells, however, it can be speculated that the
inflammatory signaling pathways mediate the transformation and aggressive phenotype
of IBC and TNBC
Collectively, RANKL and EGFR are promising targets for the development of
novel strategies to prevent or inhibit TNBC and IBC progression. Therapeutic targeting
of RANKL and EGFR using humanized monoclonal antibodies, denosumab and
panitumumab, may lead to the suppression of the inflammatory mediators produced by
RANKL/RANK and EGFR/COX-2 signaling. Abrogated signaling through these
receptors is concomitant with the downregulation of the tumor-promoting activity of
CSCs in IBC and TNBC. Measurement of the efficacy of these antibodies to target the
CSC population will occur through the detection of circulating tumor cells (CTCs) in the
peripheral blood, described as EPCAM+/CD45- (118), and disseminated tumor cells
(DTCs) or epithelial cells expressing CD326+CD45low localized to the bone can be
evaluated based on multiparameter flow cytometry analysis of CD44+CD24- and ALDH
105

activity (119). On the basis of our data, we expect that TNBC and IBC patients treated
with denosumab or panitumumab will reduce COX-2, EGFR and Nodal activity in
primary breast tumors, and reduce the number of CTCs in peripheral blood and DTCs
in bone marrow. We envision that such a therapy may prevent patient morbidity
through the elimination of de novo metastasis and improved long-term survival.
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Appendix A) TNBC and non-TNBC cell line APC-RANK median
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Appendix B) TNBC and non-TNBC cell line APC-RANK median
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